Treating infections using idsd from proteus mirabilis

ABSTRACT

The present disclosure provides, in some embodiments, compositions, kits, systems, and methods for reducing bacteria on a surface (e.g., a medical device) and preventing and/or treating a bacterial infection (e.g., urinary tract infection) in a subject using IdsD protein or a fragment thereof.

RELATED APPLICATION

This application claims priority under 35 U.S.C § 119(e) to U.S. provisional application, U.S. Ser. No. 62/375,248, filed Aug. 15, 2016, which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

Initial colonization of hosts by many species of bacteria is conferred, in part, by their ability to swarm. Swarming is a type of bacterial motility in which colonies of bacteria expand outward on a surface at centimeter-scale distances. In some species, bacterial colonies of identical populations will merge while colonies of genetically distinct populations will remain separate forming a visually apparent boundary. A boundary formed between genetically distinct populations requires that the bacteria have the ability to discriminate between self and non-self.

Proteus mirabilis is a swarming gram-negative bacterium and causative agent of urinary tract infections. Boundary formation between genetically distinct populations of the swarming bacterium P. mirabilis requires, in at least one strain, three gene clusters termed idr, tss, and ids. The idr and tss genes, which encode putative cytotoxic elements and type VI secretion (T6S) system, respectively, are needed for competition with other P. mirabilis strains and appear to evoke contact-dependent growth inhibition. The ids genes encode proteins necessary for self-recognition including IdsD protein that is exported by one cell and received by another cell. When IdsD from a donor cell (e.g., IdsD from P. mirabilis strain BB2000) interacts with IdsE in the recipient cell (e.g., IdsE from P. mirabilis strain BB20000), P. mirabilis populations are recognized as self (kin) and merge. When IdsD from a donor cell (e.g., IdsD from P. mirabilis strain BB2000) remains unbound to IdsE in the recipient cell (e.g., IdsE from P. mirabilis strain HI4320), P. mirabilis populations are recognized as non-self and form a boundary. Unbound IdsD in the recipient cell is non-lethal. Thus, IdsD and IdsE form a heteromeric bacterial self-recognition system.

SUMMARY OF THE INVENTION

Provided herein are compositions, kits, systems, and methods for reducing bacterial growth and/or swarming (e.g., on a surface) and for treating a subject having a bacterial infection (e.g., a urinary tract infection) using IdsD protein or a fragment thereof.

Bacteria, such as the swarming bacterium P. mirabilis, can come together in colonies that move rapidly across surfaces. During this swarm migration, P. mirabilis exhibits self versus non-self recognition. Populations of genetically identical organisms merge while populations of genetically different organisms separate and form a visible boundary (1-4). The ids operon, encoding six proteins IdsA to IdsF, is one of the genetic loci responsible for boundary formation (2, 5, 6). Three Ids proteins (IdsA, IdsB, and IdsD) are exported in a Type VI Secretion System (T6SS) (5, 7). T6SSs, which are widely distributed among gram-negative bacteria, are machines that can translocate proteins, primarily lethal proteins, from the inside of one cell directly into another (8-28). T6SSs have been shown to transfer lethal proteins to recipient cells, however, recipient cells many remain viable if they have an inhibitory protein that binds to and inhibits the transferred lethal protein (15, 16, 18, 21, 22, 28-30).

The present disclosure provides that IdsD protein is transferred from one cell to another in a T6SS-dependent manner where IdsD and IdsE proteins function as a bacterial self-recognition system that determines bacterial behaviors (e.g., expansion of a swarming colony) within the recipient cell. IdsD and IdsE proteins each contain a variable region, predicted to be a transmembrane region, that has a stretch of amino acids that is generally unique among strains (2, 31). IdsD and IdsE bind in vitro when the variable regions of both proteins originate from the same strain. Binding pairs of IdsD and IdsE are termed cognate (31). By contrast, when the variable regions of IdsD and IdsE do not originate from the same strain, these proteins do not bind in vitro, and the IdsD-IdsE pair is thus termed non-cognate (31).

Swarming populations of strains producing cognate IdsD-IdsE pairs merge and thus recognize each other as self; however, swarming populations of strains producing non-cognate IdsD-IdsE pairs form a visible boundary and are considered non-self (31). Without being bound by theory, the present disclosure provides that IdsD from a donor cell likely interacts with IdsE in a recipient cell, thereby merging swarming populations of donor and recipient cells. Lack of IdsD and IdsE interaction in recipient cells negatively impacts swarm colony expansion, but not viability.

The present disclosure provides compositions, kits, systems, and methods for reducing bacteria on a surface (e.g., a medical device) and preventing and/or treating a bacterial infection (e.g., urinary tract infection) in a subject using IdsD protein or a fragment thereof.

In some embodiments, the IdsD protein comprises an amino acid sequence as provided by SEQ ID NO:2 or SEQ ID NO:4, or a fragment thereof, wherein the IdsD protein comprises a variable region that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of IdsD protein as provided by SEQ ID NO:10 or SEQ ID NO:12, and wherein the amino acid sequence of the IdsD protein is not identical to the amino acid sequence of a naturally occurring Proteus mirabilis IdsD protein.

In some embodiments, the IdsD protein fragment comprises the variable region. In some embodiments, the variable region comprises an amino acid sequence as provided by SEQ ID NO:10 or SEQ ID NO:12. In some embodiments, the variable region comprises one or more mutations. In some embodiments, the one or more mutations are mutations to amino acid residues 761 and/or 765 of amino acid sequences provided by SEQ ID NO:2 or SEQ ID NO:4 or the one or more mutations are mutations to amino acid residues 1 and/or 5 of amino acid sequences provided by SEQ ID NO:10 or SEQ ID NO:12.

In some embodiments, the IdsD protein or fragment thereof is provided by nucleic acids encoding the IdsD protein or fragment thereof. In some embodiments, the nucleic acids encoding the IdsD protein or fragment thereof are provided by SEQ ID NO:1 or SEQ ID NO:3. In some embodiments, the nucleic acids encoding the IdsD protein or fragment thereof are provided by by SEQ ID NO:9 or SEQ ID NO:11.

In some embodiments, the IdsD protein is provided by a bacterial composition comprising the IdsD protein. In some embodiments, the bacterial composition comprises Proteus mirabilis.

In some embodiments, the IdsD protein is provided by a pharmaceutical composition comprising the IdsD protein and a pharmaceutically acceptable carrier. In some embodiments, the IdsD protein further comprises one or more therapeutic agents. In some embodiments, the therapeutic agent is an antibiotic.

In some embodiments, the disclosure provides a method of reducing bacterial growth and/or swarming on a surface comprising contacting or coating the surface with IdsD protein. In some embodiments, contacting or coating comprises spraying, brushing, applying, and/or treating the surface with IdsD protein.

In some embodiments, the disclosure provides a method for reducing the occurrence of urinary tract infections in a subject with a medical device comprising coating of a medical device with IdsD protein and implanting the device in a subject. In some embodiments, the medical device is a catheter, sphincter, dilator, stent, tissue bonding device, graft, drain tube, shunt, joint replacement, pacemaker system, valve, or prosthesis. In some embodiments, the subject is a human.

In some embodiments, the disclosure provides a method for treating or preventing a bacterial infection, the method comprising administering to a subject in need thereof a therapeutically effective amount of IdsD protein. In some embodiments, the bacterial infection is a urinary tract infection. In some embodiments, the urinary tract infection is a catheter-associated urinary tract infection. In some embodiments, the bacterial infection is a Proteus mirabilis infection. In some embodiments, the method further comprises screening the Proteus mirabilis infection for IdsD and/or IdsE. In some embodiments, screening the Proteus mirabilis infection for IdsD and/or IdsE comprises sequencing assays, binding assays, and/or boundary formation assays. In some embodiments, the method further comprises administering one or more other therapeutic agents. In some embodiments, the other therapeutic agent is an antibiotic. In some embodiments, the subject is human.

In some embodiments, the disclosure provides a medical device kit comprising a medical device and IdsD protein. In some embodiments, the medical device is a catheter, sphincter, dilator, stent, tissue bonding device, graft, drain tube, shunt, joint replacement, pacemaker system, valve, or prosthesis.

These and other aspects and embodiments of the invention will be described in greater detail herein. The description of exemplary embodiments of IdsD protein is provided for illustration purposes only and not meant to be limiting. Additional compositions, kits, systems, and methods (e.g., variations of IdsD protein described in detail above) are also embraced by this disclosure.

The summary above is meant to illustrate, in a non-limiting manner, some of the embodiments, advantages, features, and uses of the technology disclosed herein. Other embodiments, advantages, features, and uses of the technology disclosed herein will be apparent from the Detailed Description, the Drawings, the Examples, and the Claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-1D shows binding of IdsD (D) and IdsE (E) regulate P. mirabilis swarming.

FIG. 1A shows a plot of colony expansion of monoclonal P. mirabilis swarms after 16 hours on swarm-permissive agar surfaces. Variable region (VR) identities of the produced IdsD and IdsE variants are indicated for each strain. Widths of individual swarm rings within a swarm colony are marked by different shades. N=16, error bars show standard deviations of individual swarm ring widths.

FIG. 1B shows representative pictures of each strain from FIG. 1A that were taken 24 hours after inoculation.

FIG. 1C shows a plot of viable cells per monoclonal swarm colony after 16 hours on swarm-permissive agar surfaces. Strain descriptions are found in FIG. 1D. N=12.

FIG. 1D shows a plot of diameters of monoclonal colonies in 0.3% LB medium after 9 hours. N=6.

FIG. 2A-2C shows IdsD is transferred between cells.

FIG. 2A shows representative pictures of swarm colony expansion and competing mechanistic models for the mode of IdsD-IdsE interactions. FIG. 2A, left panel, shows a schematic depiction of intercellular, T6SS459 dependent (grey arrow) communication of IdsD from one cell (double-walled oval) to a neighboring cell. Binding to IdsE in the recipient cell allows for colony expansion to proceed, while lack thereof impairs colony expansion. This communication is bidirectional if both cells have a functional T6SS. FIG. 2A, right panel, shows a schematic depiction of swarm colony expansion depending on the binding states of the IdsD and IdsE variants produced within an individual cell.

FIG. 2B shows representative western blots of supernatants of strains carrying either the 464 empty vector pKG101 (6) or pLW101, which produces IdsA [T6SS_Hcp (PF05638)] with a C-terminal FLAG tag, were subjected to trichloroacetic acid precipitations. Whole cell extracts were obtained as well. All samples were analyzed using Western blot analysis. The BB2000-derived vipA::Tn5 strain contains a chromosomal transposon insertion in the gene encoding VipA [T6SS_VipA (PF05591)] (5), which is essential for export of T6SS-related factors and was used as a control. Blots were probed with antibodies against FLAG to detect IdsA-FLAG and against σ⁷⁰, a bacterial protein transcription initiation factor used as a cell lysis control.

FIG. 2C shows representative pictures of swarm-permissive agar surfaces inoculated with Aids-derived (export-active, donor) strains on the left side and CCS05-derived (export-inactive, recipient) strains on the right side. Each strain produces the indicated IdsD and IdsE variants. Variable region exchanges from BB2000 (BB) to HI4320 (HI) are indicated with the prefix “VR”. D_(HI) and E_(HI) are IdsD and IdsE variants derived completely from HI4320. Black outlines are shows combinations of swarms that merged. Arrowheads indicate where opposing swarm colonies intersect.

FIG. 3A-3B shows unbound IdsD in a recipient cell impairs swarm colony expansion.

FIG. 3A shows a plot of colony expansion as described in FIG. 1A. Strains were inoculated either as monoswarms (export-active donor CCS06 or export-inactive recipient CCS05-derivatives) or as coswarms (CCS06 and CCS05-derivatives) at a 1:1 ratio. IdsD and IdsE variants produced by strains derived from CCS05 are indicated. CCS06 lacks IdsE, but produces D_(VR-BB). Error bars, standard deviations for each swarm ring width (N=3 for monoswarms and coswarms of D_(VR-BB)E_(VR-HI) and D_(VR-HI)E_(VR-HI), n=6 for all others). Fold changes of total colony expansion between monoswarms and coswarms are indicated. * marks a significant change (p<0.005, two-tailed t test). na, not applicable.

FIG. 3B shows representative pictures of monoswarms and coswarms taken 24 hours after inoculation. Insets show models of intercellular, T6SS-dependent (grey arrow) communication of D_(VR-BB) from an export-active cell (CCS06, grey) to its neighboring cell, whether export-active (grey) or export inactive (CCS05-derivative, white).

FIG. 4 shows a plot of colony expansion of monoclonal swarms after 16 hours on swarm-permissive agar surfaces. Widths of individual swarm rings within a swarm colony are marked by different shades. N=16, error bars show standard deviations of individual swarm ring widths. Data from strain CCS01 is the same as in FIG. 1A.

FIG. 5A-5B shows viability on surfaces and generation times in liquid are unaltered when IdsD and IdsE are noncognate.

FIG. 5A shows a plot of viable cells per swarm colony over time on swarm-permissive agar surfaces. IdsD and IdsE variants produced by the different strains are indicated in FIG. 4B. N=4, error bars show standard deviations. Viability on surfaces are unaltered when IdsD and IdsE are noncognate.

FIG. 5B shows a plot of generation times during logarithmic growth in liquid medium. N=6. Boxes range from the 25^(th) to the 75^(th) percentile, lines within boxes indicate medians, and whiskers indicate minima and maxima.

FIG. 6 shows representative western blots of subcellular fractions of swarming BB2000 and of whole cell extract of Aids, probed for the presence of IdsD, IdsE, and σ⁷⁰. A band for σ⁷⁰ was seen in all fractions. No bands corresponding to IdsD or IdsE were observed in the cytoplasmic fraction. W, whole cell extract; C, cytoplasmic fraction; IM+, inner membrane fraction plus proteins that were not fully solubilized in prior steps; P, periplasm fraction; OM+, outer membrane fraction plus proteins that where not fully solubilized in prior steps.

DEFINITIONS

The term “administer,” “administering,” or “administration” refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing recombinant IdsD protein as described herein, or a composition thereof, in or on a subject.

Bacterial infections include, but are not limited to, gram-negative bacterial infections, gram-positive bacterial infections, and other bacterial infections. Exemplary bacterial infections include, but are not limited to, infections with a gram positive bacteria (e.g., of the phylum Actinobacteria, phylum Firmicutes, or phylum Tenericutes); gram negative bacteria (e.g., of the phylum Aquificae, phylum Deinococcus-Thermus, phylum Fibrobacteres/Chlorobi/Bacteroidetes (FCB), phylum Fusobacteria, phylum Gemmatimonadest, phylum Ntrospirae, phylum Planctomycetes/Verrucomicrobia/Chlamydiae (PVC), phylum Proteobacteria, phylum Spirochaetes, or phylum Synergistetes); or other bacteria (e.g., of the phylum Acidobacteria, phylum Chlroflexi, phylum Chrystiogenetes, phylum Cyanobacteria, phylum Deferrubacteres, phylum Dictyoglomi, phylum Thermodesulfobacteria, or phylum Thermotogae).

The term “boundary formation,” as used herein refers to a macroscopically visible boundary of up to 3 mm formed when swarming populations of bacteria (e.g., P. mirabilis) meet and recognize each other as non-self. In contrast, swarming populations of bacteria (e.g., P. mirabilis) that meet and recognize each other as self merge to form a single larger swarm.

The term “coating”, as used herein, refers to a layer of recombinant IdsD protein covering a surface. The coating can be applied to the surface or impregnated into the material of the surface. The coating may comprise any recombinant IdsD protein suitable for inhibiting the growth or motility of bacteria.

The term “cognate,” as used herein, refers to IdsD and IdsE proteins that interact. Cognate IdsD-IdsE proteins may refer to recombinant proteins or proteins in P. mirabilis.

An “effective amount” of a compound described herein refers to an amount sufficient to elicit the desired biological response. An effective amount of a compound described herein may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. In certain embodiments, an effective amount is a therapeutically effective amount. In certain embodiments, an effective amount is a prophylactic treatment. In certain embodiments, an effective amount is the amount of a compound described herein in a single dose. In certain embodiments, an effective amount is the combined amounts of a compound described herein in multiple doses.

The “percent identity” of two amino acid sequences is determined using the algorithm of Karlin and Altschul Proc. Natl. Acad. Sci. USA 87:2264-68, 1990, modified as in Karlin and Altschul Proc. Natl. Acad. Sci. USA 90:5873-77, 1993. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. J. Mol. Biol. 215:403-10, 1990. BLAST protein searches can be performed with the XBLAST program, score=50, word length=3 to obtain amino acid sequences homologous to the protein molecules of interest. Where gaps exist between two sequences, Gapped BLAST can be utilized as described in Altschul et al., Nucleic Acids Res. 25(17):3389-3402, 1997. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

A “prophylactically effective amount” of a compound described herein is an amount sufficient to prevent a condition, or one or more symptoms associated with the condition or prevent its recurrence. A prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the condition. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.

The term “inhibition,” as used herein, refers to inhibition of a pathogenic bacteria including the inhibition of any desired function or activity of the bacteria such as bacterial growth, colonization, or swarming. Inhibition of bacterial growth may include inhibition of the size of the pathogenic bacteria and/or inhibition of the proliferation or multiplication of the pathogenic bacteria. Inhibition of colonization of a pathogenic bacteria may include inhibition of the amount of bacteria and may be demonstrated by measuring the amount of the pathogenic bacteria before and after a treatment. Inhibition or inhibiting includes total and partial reduction of one or more activities of a pathogenic bacteria.

The term “medical device,” as used herein, refers to any material, natural or artificial, that is inserted into a subject (e.g., mammal, such as a human). Examples of medical devices suitable for coating with Proteus mirabilis IsdD, as provided herein, include, but are not limited to, catheters such as urinary catheters, venous catheters, arterial catheters, dialysis catheters, peritoneal catheters, urinary sphincters, urinary dilators, urinary stents, tissue bonding urinary devices, vascular grafts, vascular dialtors, extravascular dilators, vascular stents, extravascular stents, wound drain tubes, shunts, pacemaker systems, joint replacements, heart valves, cardiac assist valves, bone prosthesis, joint prosthesis, or dental prosthesis.

The term “mutation,” as used herein, refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or a deletion or insertion of one or more residues within a sequence. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual (4^(th) ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)).

The term “non-cognate,” as used herein, refers to IdsD and IdsE proteins that do not interact. Non-cognate IdsD-IdsE proteins may refer to recombinant proteins or proteins in P. mirabilis.

The term “non-pathogenic bacteria,” as used herein, refers to any known or unknown non-pathogenic bacteria (gram positive or gram negative) and any pathogenic bacteria that has been mutated or converted to a non-pathogenic bacteria. Bacteria may be pathogenic to specific species and non-pathogenic to other species, and thus bacteria can be utilized in the species in which it is non-pathogenic.

The terms “nucleic acid” and “nucleic acid molecule,” as used herein, refer to a compound comprising a nucleobase and an acidic moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides. Typically, polymeric nucleic acids, e.g., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage. In some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g. nucleotides and/or nucleosides). In some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms “oligonucleotide” and “polynucleotide” can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides). In some embodiments, “nucleic acid” encompasses RNA as well as single and/or double-stranded DNA. Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, an mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule may be a non-naturally occurring molecule, e.g., a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA/RNA hybrid, or including non-naturally occurring nucleotides or nucleosides. Furthermore, the terms “nucleic acid,” “DNA,” “RNA,” and/or similar terms include nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications. A nucleic acid sequence is presented in the 5′ to 3′ direction unless otherwise indicated. In some embodiments, a nucleic acid is or comprises natural nucleosides (e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose); and/or modified phosphate groups (e.g., phosphorothioates and 5′-N-phosphoramidite linkages).

The term “pathogenic bacteria,” as used herein, refers to any bacteria or any other organism that is capable of causing or affecting a disease, disorder, or condition of a host organism.

The term “pharmaceutical compositions,” as used herein, refer to any compositions prepared by any method known in the art of pharmacology. In general, such preparatory methods include bringing the “active ingredient,” for example, recombinant IdsD protein as described herein, into association with a carrier or excipient, and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.

The terms “protein,” “peptide,” and “polypeptide” are used interchangeably herein, and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long. A protein, peptide, or polypeptide may refer to an individual protein or a collection of proteins. One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. A protein, peptide, or polypeptide may also be a single molecule or may be a multi-molecular complex. A protein, peptide, or polypeptide may be just a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination thereof. The term “fusion protein” as used herein refers to a hybrid polypeptide which comprises protein domains from at least two different proteins. One protein may be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxy-terminal (C-terminal) protein thus forming an “amino-terminal fusion protein” or a “carboxy-terminal fusion protein,” respectively. A protein may comprise different domains, for example, a variable domain (e.g., the variable domain in IdsD) and a T6S-associated motif. Any of the proteins provided herein may be produced by any method known in the art. For example, the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker. Methods for recombinant protein expression and purification are well known, and include those described by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4^(th) ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)), the entire contents of which are incorporated herein by reference.

The term “Proteus mirabilis IdsD” and “D,” as used herein, refers interchangeably to Proteus mirabilis IdsD. In some embodiments, Proteus mirabilis IdsD corresponds to IdsD from Proteus mirabilis strain BB2000 (NCBI Reference Sequence: EU635876.1:6035 . . . 9139, SEQ ID NO:1 (nucleotide) or SEQ ID NO:2 (amino acid)).

(SEQ ID NO: 1) ATGACTGGAGAAGTGAATGAGAAATATTTAACACCGCAAGAGCGCAAAG CGCGTCAGATGGTGAAGGCGGTAAACGAAGCGAGCCCACGAAACTTACC GGCCGACGCGGTGGTATGCCCATGTGAAAATGAACATCGCCCTGTTTAT CCGGTGCGTTATGCATATACCAACTTTTATTGTGATTTACATTTTTCTA CAATTGAACAAGCACCAAATAAAACGTTAGAAGCGAGTATTCCTCCTTC TATTAATCAATTATTGAATGCGAAAGATGTTACTGCTAGTAAAGGATTT TCTGCAAGATTATTAAGACAAGGTTGGGTTTATGTTTTTGAAGAAGGCA ATTACCCTACTAGAAGTAATTCTAGCAATAAAAGTTATCAAGAACAAAA TGTTGATGCAACAAAAGGACGCCTATTAGTTTTTCAACATCAAGTGACA ACCAGTGATGGCAATGAAAATTTCATTCCATATATATTTAAGCAATTAA AAAATGGGGGTGTCACTTTAAAGAAAAACGGAAATAGTAATCCTTATTT AGCTATACCGAAAGATGTGAAGGAAGCGACTATCTTATTCAGCGAAAGT AAATTATCTGATTACACACTTAAAAAAATCATTTCATCTTCTAAGTTTA GATCGAAATTAATGCAAAAAATCAATTTTATTGATTACAATAATAACGA TTATTGTATTGAGCTAAATAAAGATAATTTAAATCGACTTGTTGAGGAT TATAAAGAAGAAGTTGATAAATTTAAGCTATTTGTTAAAGAATTCACGC ATTCAAATATACCCTCTTCTTTTTTTTCTGATACCACAAAAATACCCGA CTTACCACAAGATGCAACTGTTTTGATTAATCAAGTAAATAGTGTTCTA GATTATAATGAAAAAGCGACATTGCTTATTTTAAAAGATCCCGTAGGAT ACCAAAAAGATATTTTATCTTATTATAATATTGTAACAAAATTACATTT ATTATATCAGAACTATTATAGCCATCCGGATAAAATTGGCCAATTTATT ACGAGTATACAAGAAGCTAGTCATCACATTAAAGATACTGATGAAAAAG AAAAAATGCAAACAATACTAAAAGAGAGTATTAATCAGAATGCATTAGA TAATGAGTGGAAAAATATTCATAAAACATTTATTTTTTTTGAGAAACAT CAACGTATTGTATTATCATTGTATGAAAGCTTTATGAATAATCCGGCAA TCATTAATGAAAACGGTGGCTTAAAACATTATTTTGATTATGCTTTTTC ATATCACGAACGTATAACTAAAGAAGATGTCTTTAGTATTGATTTTTTT AAGGACCTTAATCAAGCTTTTGATTTATATTTTGATTTAGTATCTCCAT TAATGAATTCTATCGAAGGACAAAGAACATTAGATAAATTATATTCAAT TAATGATGAAGAAAATAATAGCCTGTGGGTGGGAGTGACAAAGAAAGTA ATTAGTCTTATTGCTAATTCAAAAATTAAGGACGCTCTTTTAAATGTAC AAGAATATGCAATGCATATCGAAAATTTTGTTAATAAGCTTGCATTTAT TTGCTCAGATAGCATTGGTTTCGCGTTTACAAAAACAAGTAAGGTACTT TCTCATTACGATATTAAAAATAGACTAATTAATACTAAGGGTATTGACT ATTTAGCCCAAAAGATACTTCCGATGATACTGGCATTTTGCAACACAAA AATTTCATTAACCGAGTTTGTTAAATTATCGGGTAATGAGCTTAACCAG TGGATGGAACAACTCCGTAAATTAACGGGACAAATAGTACCAAATCTGC AACATCCTAAATTAAATAAGCTTTTTTCTTGGAAACAAAAAATAATAAA TCTAGGCGAAGAGACTGCCGTTCTTATTCCGAAGATTGAGATCATAGAT ATTACTAAAAATAAGATTTATATTTATGGCAAAGATGCATTACAGGTTT CCACTAAGCTATTTTTAAACGGTTTCAGCATGATCACCGGATCAATCCA AGCTTATACATTACAAGGTATGAGTTTGTATGAACGTAATGACCCATTA AAACTATCCCCCTATAATCTGTATACAGCACAGATTATTGCGAATTTAT TTGTAGCAAGCTACAGTATTTTAAAAGTTTCTCAAGAGGCGACAAAATT ATCTCAAACAGTATCGAGCACCACACTGAAATTCTTTTTAGATAAAATA AAATTACCTATGCTAACAACAGAAGTGGGAACCAAAAGAATGGCAGCAT TAGGTAAGATTGCAGGTGCCGTTGGTGCCGCTCTTGCCGCTCGTGACGC ATTAGAAGCTTTTCATATTGGAAATTATAAACAATCTGTATCAAATATA GCTATTGTGATTGGTTCTATAATTTTAATTACTGCTGTTACTGGAGGAT GGGCTTTATTTGCTGGGGCACTTATTTTGGGGGGATTTATCTCAAGCCA ACTCACCAGTTGGAGTCATTTAGAAACTTTACTAAAACATAGTTTTTGG GGGAATGAAAAAAGGTCTAATTTTTGGGATAATGATAGACCAACACCGA TAGGAGAACAATTAAAACAATATATAAAAGAATTTGAATTCTATAAACA AAAAGGGCTAATTGAATTACAAGAGTTTTATAATCTATTTTATACAGCT AAAATGACTCAAGAAAAAATACCAAATGGAAAACTCCGCTTATCTTTTG AATTTACTAATTTTACCCCAGGGATTTCAGAAGTATATTTTCACTTTGT TACAGAGGTTGGTTATCACAGCGGCTTGGCAGAAGAAATAAAAACACCT AGTTCAGCTTATGTTCTAAATAAACGAAAAGACCTCTTAGAAATTAGCG AACAATTAAAAATGGCAAGTGAAAAAGGTGATTGGAACCCTGAAACAGG TATATTTAAATTTAGTTTGGAAGTACAGTCTCAATTAGTAAATACATAT TCTGCTTTTGGTGCACATCCTAATAGCCGTATAGGTATTGAAGATTTAT ATTGGTATTATCAAGTCAATCCCGAGGTAACAACACCGATGCGTTATAT CAATTGGGGGGGAGATACCCAAGAAAACAATCAGCTTTTAGGCTTTATT AACAGTGAGAATATCTAA (SEQ ID NO: 2) MTGEVNEKYLTPQERKARQMVKAVNEASPRNLPADAVVCPCENEHRPVY PVRYAYTNEYCDLHFSTIEQAPNKTLEASIPPSINQLLNAKDVTASKGF SARLLRQGWVYVFEEGNYPTRSNSSNKSYQEQNVDATKGRLLVFQHQVT TSDGNENFIPYIFKQLKNGGVTLKKNGNSNPYLAIPKDVKEATILFSES KLSDYTLKKIISSSKFRSKLMQKINFIDYNNNDYCIELNKDNLNRLVED YKEEVDKFKLFVKEFTHSNIPSSFFSDTTKIPDLPQDATVLINQVNSVL DYNEKATLLILKDPVGYQKDILSYYNIVTKLHLLYQNYYSHPDKIGQFI TSIQEASHHIKDTDEKEKMQTILKESINQNALDNEWKNIHKTFIFFEKH QRIVLSLYESFMNNPAIINENGGLKHYFDYAFSYHERITKEDVFSIDFF KDLNQAFDLYFDLVSPLMNSIEGQRTLDKLYSINDEENNSLWVGVTKKV ISLIANSKIKDALLNVQEYAMHIENFVNKLAFICSDSIGFAFTKTSKVL SHYDIKNRLINTKGIDYLAQKILPMILAFCNTKISLTEFVKLSGNELNQ WMEQLRKLTGQIVPNLQHPKLNKLFSWKQKIINLGEETAVLIPKIEIID ITKNKIYIYGKDALQVSTKLFLNGFSMITGSIQAYTLQGMSLYERNDPL KLSPYNLYTAQIIANLFVASYSILKVSQEATKLSQTVSSTTLKFFLDKI KLPMLTTEVGTKRMAALGKIAGAVGAALAARDALEAFHIGNYKQSVSNI AIVIGSTILTTAVTGGWALFAGALILGGFISSQLTSWSHLETLLKHSFW GNEKRSNFWDNDRPTPIGEQLKQYIKEFEFYKQKGLIELQEFYNLFYTA KMTQEKIPNGKLRLSFEFTNFTPGISEVYFHFVTEVGYHSGLAEEIKTP SSAYVLNKRKDLLEISEQLKMASEKGDWNPETGIFKFSLEVQSQLVNTY SAFGAHPNSRIGIEDLYWYYQVNPEVTTPMRYINWGGDTQENNQLLGFI NSENI (underline: variable region)

In some embodiments, Proteus mirabilis IdsD corresponds to IdsD from Proteus mirabilis strain HI4320 (NCBI Reference Sequence: NC_010554.1:3282912 . . . 3286013, SEQ ID NO:3 (nucleotide) or SEQ ID NO:4 (amino acid)).

(SEQ ID NO: 3) ATGACTGGAGAAGTGAATGAGAAATATTTAACACCGCAAGAGCGCAAAG CGCGTCAGATGGTGAAGGCGGTAAACGAAGCGAGCCCACGAAACTTACC GGCCGACGCGGTGGTATGCCCATGTGAAAATGAACATCGCCCTGTTTAT CCGGTGCGTTATGCATATACCAACTTTTATTGTGATTTACATTTTTCTA CAATTGAACAAGCACCAAATAAAACGTTAGAAGCGAGTATTCCTCCTTC TATTAATCAATTATTGAATGCGAAAGATGTTACTGCTAGTAAAGGATTT TCTGCAAGATTATTAAGACAAGGTTGGGTTTATGTTTTTGAAGAAGGCA ATTACCCTACTAGAAGTAATTCTAGTAATAAAAGTTATCAAGAACAAAA TGTTGATGCGACAAAAGGACGCCTATTAGTTTTTCAACATCAAGTTACA ACCAGTGATGGCAATGAAAATTTCATTCCATATATATTTAAGCAATTAA AAAATGGGGGTGTCACTTTAAAGAAAAACGGAAATAGTAATCCTTATTT AGCTATACCGAAAGATGTGAAGGAAGCGACTATCTTATTCAGCGAAAGT AAATTATCTGATTACACACTTAAAAAAATCATTTCATCTTCTAAGTTTA GATCGAAATTAATGCAAAAAATCAATTTTATTGATTACAACAATAACGA TTATTGTATTGAGCTAAATAAAGATAATTTAAATCGACTTGTTGAGGAT TATAAAGAAGAAGTTGATAAATTTAAGCTATTTGTTAAAGAATTCACGC ATTCAAATATACCCTCTTCTTTTTTTTCTGATACCACAAAAATACCCGA CTTACCACAAGATGCAACTGTTTTGATTAATCAAATAAATAGTGTTCTA GATTATAATGAAAAAGCGACATTGCTTATTTTAAAAGATCCCGTAGGAT ACCAAAAAGATGTTTTATCTTATTATAATATTGTAACAAAATTACATTT ATTATATCAGAACTATTATAGCCATCCGGATAAAATTGGCCAATTTATT ACGAGTATACAAGAAGCTAGTCATCACATTAAAGATACTGATGAAAAAG AAAAAATGCAAACAATACTAAAAGAGAGTATTAATCAGAATGCATTAGA TAATGAGTGGAAAAATATTCATAAAACATTTATTTTTTTTGAGAAACAT CAACGTATTGTATTATCATTGTATGAAAGCTTTATGAATAATCCGGCAA TCATTAATGAAAACGGTGGCTTAAAACATTATTTTGATTATGCTTTTTC ATATCACGAACGTATAACGAAAGAAGATGTCTTTAGTATTGATTTTTTT AAGGACCTTAATCAAGCTTTTGATTTATATTTTGATTTAATATCTCCAT TAATGAATTCTACCGAAGGACAAAGAACATTAGATAAATTATATTCAAT TAATGATGAAGAAAATAATAGCCTGTGGGTGGGAGTGACAAAGAAAGTA ATTAGTCTTGTTGCTAATTCAAAAATTATGGACGCACTTTTAAATGCAC AAGAATATGCAGAGAATATCGAAAATTTTGTTAATAAGCTTGCGTTTAT TTGCTCAGATAGCATTGGTTTTGCATTTACAAAAACAAGTAAGATGCTT TCTCATTACGATATTAAAAATAGACTAATTAATACTAAGGGTATTGACT ATTTAGCTCAAAAGATACTTCCGATGATACTGGCATTTTGCAACACAAA AATTTCATTAACCGAGTTTGTTAAATTATCGGGTAATGAGCTTAACCAG TGGGTGGAACAACTCCGTAAATTAACGGAACAAATAGTACCAAATCTGC AACATCCTAAATTAAATAAGCTTTTTTCTTGGAAACAAAAAATAATAAA TCTAGGCGAAGAGACTGCCGTTCTTATTCCGAAGATTGAGATCACAGAT ATTACTAAAAATAAGATTTATATTTATGGTAAAGATGCATTACAGGTTT CCACTAAGCTATTTTTAAACGGTTTCAGCATGATCACCGGATCAATCCA AGCTTATACATTACAAGGTATGAGTTTGTATGAACGTAATGACCCATTA AAACTATCCCCCTATAATCTGTATACAGCACAGATTATTGCGAATTTAT TTGTAGCAAGCTACAGTATTTTAAAAGTTTCTCAAGAGGCGACAAAATT ATCTCAAACAGTATCGAGCACCACACTGAAATTCTTTTTAGATAAAATA AAATTACCTATGCTAACAACAGAAGTGGGAACCAAAAGAATGGCAGCAT TAGGTAAGATTGCAGGTGCCGTTGGTGTTGCTCTTGCCACTCGAGATGC ATTAGAAGCTTTTCATATTGGAAATAATAAACAAGGTTTATCAAATGTA GCCATTGCCATTGGTTCTTTCATGCTAATTTTTGTTACAGGGGGATGGG CTCTATTTGCAGGACTGCTAATATTAGGAGGCTTCTTCTCAAGTCAACT CACCAGTTGGAGTCATTTGGAAACTTTGCTAAGGCACAGTTTTTGGGGA AATGAAGAAAGTTCAAATTTTTGGGATAATAATAGACCAACACCGATAG GAGAACAATTAAAACAATATATAAAAGAATTTGAATTCTATGAACAAAA AGGGCTAATTGAATTACAAGAGTTTTATAATCTATTTTATACAGCTAAA ATGACTCAAGAAAAAATACCAAATGGAAAACTCCGCTTATCTTTTGAAT TTACTAATTTTACCCCAGGGATTTCAGAAGTATATTTTCACTTTGTTAC AGAGGTTGGTTATCACAGCGGCTTGGCAGAAGAAATAAAAACACCTAGT TCAGCTTATGTTCTAAATAAACGAAAAGACCTCTTAGAAATTAGCGAAC AATTAAAAATGGCAAGTGAAAAAGGTGATTGGAACCCTGAAACAGGTAT ATTGAAATTTAGTTTGGAAGTACAGTCTCAATTAGTAAATACATATTCT GCTTTTGGTGCACATCCTAATAGCCGTATAGGTATTGAAGATTTATATT GGTATTATCAAGTCAATCCCGAGGTAACAACACCGATGCGTTATATCAA TTGGGGGGGAGATACCCAAGAAAACAATCGGCTTTTAGGCTTTATTAAC AGTGAGAATATCTAA (SEQ ID NO: 4) MTGEVNEKYLTPQERKARQMVKAVNEASPRNLPADAVVCPCENEHRPVY PVRYAYTNEYCDLHFSTIEQAPNKTLEASIPPSINQLLNAKDVTASKGF SARLLRQGWVYVFEEGNYPTRSNSSNKSYQEQNVDATKGRLLVFQHQVT TSDGNENFIPYIFKQLKNGGVTLKKNGNSNPYLAIPKDVKEATILFSES KLSDYTLKKIISSSKFRSKLMQKINFIDYNNNDYCIELNKDNLNRLVED YKEEVDKFKLFVKEFTHSNIPSSFFSDTTKIPDLPQDATVLINQINSVL DYNEKATLLILKDPVGYQKDVLSYYNIVTKLHLLYQNYYSHPDKIGQFI TSIQEASHHIKDTDEKEKMQTILKESINQNALDNEWKNIHKTFIFFEKH QRIVLSLYESFMNNPAIINENGGLKHYFDYAFSYHERITKEDVFSIDFF KDLNQAFDLYFDLISPLMNSTEGQRTLDKLYSINDEENNSLWVGVTKKV ISLVANSKIMDALLNAQEYAENIENFVNKLAFICSDSIGFAFTKTSKML SHYDIKNRLINTKGIDYLAQKILPMILAFCNTKISLTEFVKLSGNELNQ WVEQLRKLTEQIVPNLQHPKLNKLFSWKQKIINLGEETAVLIPKIEITD ITKNKIYIYGKDALQVSTKLFLNGFSMITGSIQAYTLQGMSLYERNDPL KLSPYNLYTAQIIANLFVASYSILKVSQEATKLSQTVSSTTLKFFLDKI KLPMLTTEVGTKRMAALGKIAGAVGVALATRDALEAFHIGNNKQGLSNV AIAIGSFMLIFVTGGWALFAGLLILGGFFSSQLTSWSHLETLLRHSFWG NEESSNFWDNNRPTPIGEQLKQYIKEFEFYEQKGLIELQEFYNLFYTAK MTQEKIPNGKLRLSFEFTNFTPGISEVYFHFVTEVGYHSGLAEEIKTPS SAYVLNKRKDLLEISEQLKMASEKGDWNPETGILKFSLEVQSQLVNTYS AFGAHPNSRIGIEDLYWYYQVNPEVTTPMRYINWGGDTQENNRLLGFIN SENI (underline: variable region)

The terms “P. mirabilis IdsE” and “E,” as used herein, refers interchangeably to Proteus mirabilis IdsE. In some embodiments, Proteus mirabilis IdsE corresponds to IdsE from Proteus mirabilis strain BB2000 (NCBI Reference Sequence: EU635876.1:9139 . . . 10077, SEQ ID NO:5 (nucleotide) or SEQ ID NO:6 (amino acid)).

(SEQ ID NO: 5) ATGAGTATTTTTTTTAATCCCGCTAAACACCCACATCGCTTAAAGCCAC AACCATTAGGGACGCAAGGCGAGCACTATAACGAAGATTGGCCCATGCC TGAGCTCGATTTTTTAGAGACCGTAGATAAACAACAGTGCATTCTGGTT GATAAAGAAATACGCCGACGTGATGCGTTTGCTTTCCCTGGGTTTATTA CCGGTATTATTACCTTTATTATGGTGTTTCATTTTGTTTTTACAGAACA TAATTCAAAGTATATCCGTTTTAATAAAAATCTTCATGACTATACATTA GAATATAAAGCCCAATATGAAGATAAAGCCCAAAGAGATAAACTACCTT CATTTATACTTGATAAGTACGCCCCTTATTTCAATCAAGAAAAACTGTC TATTTTAGATTATATTCATGTTTATTTTGGGGGTCATATTACATCAACC CCTTATATTGATACTTCCATTTTGTCTACCCTACTCATTTCATTAGTTT ATTTAATTGTAGTATCTGGCTATCAATCTTTTTTCAAAAAAAATCCAAT ACTCGTTTTTAATCGTGAAAGAAATCTGGTCTATACTTGGCGCAAAAAT AAGGTATTTATTGCCCGCTATCCTGAAATTGGTATCGGTAAAATTGGTA AAACACTTACCTTTCAATTATTCGGGTTAGATAAGTCAAAACAAACTTT AGTTTCTGAATTGTTTTTCCCTAATGTCTATGTTTATTCAGTCTACAAT ACCAGTACTGACTATCACGACCAGCGCTTCATTAATTTTATCAATACTT ATATGCGCGAAGGGCGTGATGCCATTATTCCATTCGATTATCACCGTAA AAAACCCAAAGTGTATTTTGGCAAAAACCCACCTCCTGCTGATTTTGAA CAACAGGTCGAACAAATTTTAGCAAAGCTTGATCAGGAGAAAGAACACC ATGCGTAG (SEQ ID NO: 6) MSIFFNPAKHPHRLKPQPLGTQGEHYNEDWPMPELDFLETVDKQQCILV DKEIRRRDAFAFPGFITGIITFIMVFHFVFTEHNSKYIRFNKNLHDYTL EYKAQYEDKAQRDKLPSFILDKYAPYFNQEKLSILDYIHVYFGGHITST PYIDTSILSTLLISLVYLIVVSGYQSFFKKNPILVFNRERNLVYTWRKN KVFIARYPEIGIGKIGKTLTFQLFGLDKSKQTLVSELFFPNVYVYSVYN TSTDYHDQRFINFINTYMREGRDAIIPFDYHRKKPKVYFGKNPPPADFE QQVEQILAKLDQEKEHHA (underline: variable region)

In some embodiments, Proteus mirabilis IdsE corresponds to IdsE from Proteus mirabilis strain HI4320 (NCBI Reference Sequence: NC_010554.1:3286013 . . . 3286951, SEQ ID NO:7 (nucleotide) or SEQ ID NO:8 (amino acid)).

(SEQ ID NO: 7) ATGAGTATTTTTTTCAATCCCGCTAAACACCCACATCGCTTGAAGCCAC AACCATTGGGGGAGCAAGGTGAGCGCTATAACGAAGATTGGCCCATGCC TGAGCTCGATTTTTTAGAGACCGTGGATAAACAACAGTGCATTCTGGTT GATAAAGAAATACGCCGACGTGATGCGTTTGCTTTCCCTGGGTTTATTA CCGGTATTATTACCTTTATTATGGTATTTCATTTTGTTTTTACAGAACA TAATTCAAAGTATATCCGTTTTAATAAAAATCTTCATGACTATACATTA GAATATAAAGCGCAATATGAAGATAAAACTCAAAGAGATAAACTACCTT CATTTATACTTGATAAGTACGCCCCTTATTTCAATCAAGAAAAACTGTC TATTTTAGATTATATTCATGTTTATTTTGGGGGACATATTACATCAAAA CCCTATCAAAATACGCTATTTTTTCTTTCTACTTTCATCGCACCTTTCT TCTTAATTGGCTTGGGTGGCTATCAATCTTTTTTCAAAAAAAATCCAAT ACTCGTTTTTAATCGTGAAAGAAATCTGGTTTATACTTGGCGCAAAAAT AAGGTATTTATTGCCCGCTATCCTGAAATTGGTATCGGTAAAATTGGTA AAACACTTACCTTTCAATTATTCGGGTTAGATAAGTCAAAACAAACTTT AGTTTCTGAATTATTTTTCCCTAATGTCTATGTTTATTCAGTGTACAAT ACCAGTACTGACTATCACGACCAGCGCTTCATTAATTTTATCAATACTT ATATGCGCGAAGGGCGTGATGCCATTATTCCATTCGATTATCACCGTAA AAAACCCAAAGTGTATTTTGGCAAAAACCCACCTCCTGCTGATTTTGAG CAACAGGTCGAACAGATTTTAGCAAAGCTTGATCAGGAGAAAAAACACC ATGCGTAG (SEQ ID NO: 8) MSIFFNPAKHPHRLKPQPLGEQGERYNEDWPMPELDFLETVDKQQCILV DKEIRRRDAFAFPGFITGIITFIMVFHFVFTEHNSKYIRFNKNLHDYTL EYKAQYEDKTQRDKLPSFILDKYAPYFNQEKLSILDYIHVYFGGHITSK PYQNTLFFLSTFIAPFFLIGLGGYQSFFKKNPILVFNRERNLVYTWRKN KVFIARYPEIGIGKIGKTLTFQLFGLDKSKQTLVSELFFPNVYVYSVYN TSTDYHDQRFINFINTYMREGRDAIIPFDYHRKKPKVYFGKNPPPADFE QQVEQILAKLDQEKKHHA (underline: variable region)

The term “recombinant” as used herein in the context of proteins or nucleic acids refers to proteins or nucleic acids that do not occur in nature, but are the product of human engineering. For example, in some embodiments, a recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations as compared to any naturally occurring sequence.

The term “subject,” as used herein, refers to any animal subject including humans, laboratory animals (e.g., primates, rats, mice), livestock (e.g., cows, sheep, goats, pigs, turkeys, chickens), and household pets (e.g., dogs, cats, rodents). The subject may be healthy, or may be suffering from a bacterial infection, or may be at risk of developing or transmitting to others a bacterial infection.

The term “swarming,” as used herein, refers to rapid (approximately 2-10 μm/s) and coordinated translocation of a bacterial population across solid or semi-solid surfaces. Flagellated bacteria are capable of both moving in association with other cells in a thin film of liquid over a moist surface (i.e., swarming) or moving independently in bulk liquid (i.e., swimming).

A “therapeutically effective amount” of a compound described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or causes of the condition, and/or enhances the therapeutic efficacy of another therapeutic agent.

The terms “treatment,” “treat,” and “treating,” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. As used herein, the terms “treatment,” “treat,” and “treating” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed and/or after a disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, e.g., to prevent or delay onset of a symptom or inhibit onset or progression of a disease. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.

The term “urinary tract infection,” as used herein, refers to infection of the kidney, ureter, bladder, or urethra. Cystitis is a related condition caused by bacteria entering the urethra and then the bladder, leading to inflammation and infection in the lower urinary tract. Pyelonephritis is a related condition comprising infection of the kidney and/or the ureters. Urinary tract infections may be infections of the upper urinary tract, the lower urinary tract, or both. Urinary tract infections may be chronic or acute.

The term “variable region,” as used herein, refers to interacting regions in Proteus mirabilis IdsD and IdsE that are characterized by high sequence variability and predicted transmembrane localization.

In some embodiments, the variable region in P. mirabilis IdsD corresponds to the variable region in IdsD from Proteus mirabilis strain BB2000 (NCBI Reference Sequence: EU635876.1:8316 . . . 8631, SEQ ID NO:9 (nucleotide) or SEQ ID NO:10 (amino acid)).

(SEQ ID NO: 9) GCCGCTCTTGCCGCTCGTGACGCATTAGAAGCTTTTCATATTGGAAATT ATAAACAATCTGTATCAAATATAGCTATTGTGATTGGTTCTATAATTTT AATTACTGCTGTTACTGGAGGATGGGCTTTATTTGCTGGGGCACTTATT TTGGGGGGATTTATCTCAAGCCAACTCACCAGTTGGAGTCATTTAGAAA CTTTACTAAAACATAGTTTTTGGGGGAATGAAAAAAGGTCTAATTTTTG GGATAATGATAGACCAACACCGATAGGAGAACAATTAAAACAATATATA AAAGAATTTGAATTCTATAAA (SEQ ID NO: 10) AALAARDALEAFHIGNYKQSVSNIAIVIGSIILITAVTGGWALFAGALI LGGFISSQLTSWSHLETLLKHSFWGNEKRSNFWDNDRPTPIGEQLKQYI KEFEFYK 

In some embodiments, the variable region in Proteus mirabilis IdsD corresponds to the variable region in IdsD from Proteus mirabilis strain HI4320 (NCBI Reference Sequence: NC_010554.1:3287473 . . . 3287788, SEQ ID NO:11 (nucleotide) or SEQ ID NO:12 (amino acid)).

(SEQ ID NO: 11) GTTGCTCTTGCCACTCGAGATGCATTAGAAGCTTTTCATATTGGAAATA ATAAACAAGGTTTATCAAATGTAGCCATTGCCATTGGTTCTTTCATGCT AATTTTTGTTACAGGGGGATGGGCTCTATTTGCAGGACTGCTAATATTA GGAGGCTTCTTCTCAAGTCAACTCACCAGTTGGAGTCATTTGGAAACTT TGCTAAGGCACAGTTTTTGGGGAAATGAAGAAAGTTCAAATTTTTGGGA TAATAATAGACCAACACCGATAGGAGAACAATTAAAACAATATATAAAA GAATTTGAATTCTATGAACAA (SEQ ID NO: 12) VALATRDALEAFHIGNNKQGLSNVAIAIGSFMLIFVTGGWALFAGLLIL GGFFSSQLTSWSHLETLLRHSFWGNEESSNFWDNNRPTPIGEQLKQYIK EFEFYEQ

In some embodiments, the variable region in Proteus mirabilis IdsE corresponds to the variable region in IdsE from Proteus mirabilis strain BB2000 (NCBI Reference Sequence: EU635876.1:9578 . . . 9647, SEQ ID NO:13 (nucleotide) or SEQ ID NO:14 (amino acid)).

(SEQ ID NO: 13) ACCCCTTATATTGATACTTCCATTTTGTCTACCCTACTCATTTCATTAG TTTATTTAATTGTAGTATCT (SEQ ID NO: 14) TPYIDTSILSTLLISLVYLIVVS

In some embodiments, the variable region in Proteus mirabilis IdsE corresponds to the variable region in IdsE from Proteus mirabilis strain HI4320 (NCBI Reference Sequence: NC_010554.1:3286452 . . . 3286521, SEQ ID NO:15 (nucleotide) and/or SEQ ID NO:16 (amino acid)).

(SEQ ID NO: 15) AAACCCTATCAAAATACGCTATTTTTTCTTTCTACTTTCATCGCACCTT TCTTCTTAATTGGCTTGGGT (SEQ ID NO: 16) KPYQNTLFFLSTFIAPFFLIGLG

The term “vector,” as used herein, refers to any nucleic acids capable of transferring genetic material into a cell (e.g., bacteria). The vector may be linear or circular in topology and includes, but is not limited to, plasmids or bacteriophages. The vector may include amplification genes, enhancers, or selection markers and may or may not be integrated into the genome of the host organism.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

The present disclosure provides compositions, kits, systems, and methods for reducing bacteria on a surface (e.g., a medical device) and preventing and/or treating a bacterial infection (e.g., urinary tract infection) in a subject using IdsD protein or a fragment thereof.

In some embodiments, the IdsD protein or fragment thereof comprises an amino acid sequence that is not identical to the amino acid sequence of a naturally occurring Proteus mirabilis IdsD protein. In some embodiments, the IdsD protein fragment comprises the variable region. In some embodiments, the variable region comprises one or more mutations. In some embodiments, the IdsD protein or fragment thereof is provided by nucleic acids encoding the IdsD protein or fragment thereof. In some embodiments, the IdsD protein is provided by a bacterial composition comprising the IdsD protein. In some embodiments, the bacterial composition comprises Proteus mirabilis. In some embodiments, the IdsD protein is provided by a pharmaceutical composition comprising the IdsD protein and a pharmaceutically acceptable carrier. In some embodiments, the IdsD protein further comprises one or more therapeutic agents.

In some embodiments, the disclosure provides a method of reducing bacterial growth and/or swarming on a surface comprising contacting or coating the surface with IdsD protein. In some embodiments, contacting or coating comprises spraying, brushing, applying, and/or treating the surface with IdsD protein.

In some embodiments, the disclosure provides a method for reducing the occurrence of urinary tract infections in a subject with a medical device comprising coating of a medical device with IdsD protein and implanting the device in a subject. In some embodiments, the medical device is a catheter, sphincter, dilator, stent, tissue bonding device, graft, drain tube, shunt, joint replacement, pacemaker system, valve, or prosthesis. In some embodiments, the subject is a human.

In some embodiments, the disclosure provides a method for treating or preventing a bacterial infection, the method comprising administering to a subject in need thereof a therapeutically effective amount of IdsD protein. In some embodiments, the bacterial infection is a urinary tract infection. In some embodiments, the urinary tract infection is a catheter-associated urinary tract infection. In some embodiments, the bacterial infection is a Proteus mirabilis infection. In some embodiments, the method further comprises screening the Proteus mirabilis infection for IdsD and/or IdsE. In some embodiments, screening the Proteus mirabilis infection for IdsD and/or IdsE comprises sequencing assays, binding assays, and/or boundary formation assays. In some embodiments, the method further comprises administering one or more other therapeutic agents. In some embodiments, the other therapeutic agent is an antibiotic. In some embodiments, the subject is human.

In some embodiments, the disclosure provides a medical device kit comprising a medical device and IdsD protein. In some embodiments, the medical device is a catheter, sphincter, dilator, stent, tissue bonding device, graft, drain tube, shunt, joint replacement, pacemaker system, valve, or prosthesis.

Proteus mirabilis IdsD Protein

Proteus mirabilis comprises six ids genes, idsABCDEF, encoding six proteins, IdsABCDEF. IdsD and IdsE function as a heteromeric bacterial self-recognition system as exemplified in P. mirabilis strains BB2000 and HI4320. It should be understood that P. mirabilis strains BB2000 and HI4320 are used throughout this disclosure as an exemplary embodiment and in a non-limiting manner. Thus, the various aspects and embodiments of this disclosure that refer to IdsD and IdsE from P. mirabilis strains BB2000 and HI4320 apply equally to IdsD and IdsE from any strain of P. mirabilis unless otherwise stated.

IdsD protein comprises 1,034 amino acids corresponding to SEQ ID NO:2 (strain BB2000) or SEQ ID NO:4 (strain HI4320). IdsE protein comprises 312 amino acids corresponding to SEQ ID NO:6 (strain BB2000) or SEQ ID NO:8 (strain HI4320). Without being bound by theory, IdsD and IdsE proteins function as a heteromeric bacterial self-recognition system when IdsD protein from a donor cell (e.g., donor cell is strain BB2000) interacts with IdsE protein in a recipient cell (e.g., recipient cell is strain BB2000), thereby merging swarming populations of donor and recipient cells. When IdsD protein from a donor cell (e.g., donor cell is strain BB2000) is transferred but does not interact with IdsE protein in a recipient cell (e.g., recipient cell is strain HI4320), swarm colony expansion is negatively impacted, thereby forming a boundary between swarming populations of genetically distinct bacteria. The lack of IdsD and IdsE protein interaction in recipient cells does not impact bacterial viability.

IdsD and IdsE proteins that interact, thereby merging swarming populations of bacteria are referred to as cognate IdsD-IdsE pairs. IdsD and IdsE proteins that do not interact, thereby forming a boundary between populations of bacteria are referred to as non-cognate IdsD-IdsE pairs. Interacting regions in IdsD and IdsE proteins are characterized by high sequence variability and predicted transmembrane localization. The variable region in IdsD comprises amino acid residues 761 to 865 corresponding to SEQ ID NO:2 (BB2000) or SEQ ID NO:4 (HI4320). Two residues in IdsD located at positions 761 and 765 are important for mediating interaction with the variable region in IdsE. The variable region in IdsE comprises amino acid residues 147-169 corresponding to SEQ ID NOS: 6 (BB2000) or SEQ ID NO:8 (HI4320).

Some aspects of this disclosure provide IdsD protein, or a fragment thereof, for reducing bacterial growth and/or swarming (e.g., on a surface) and for treating a subject having a bacterial infection (e.g., a urinary tract infection). Non-limiting, exemplary compositions comprising IdsD protein, or a fragment thereof, are provided herein.

IdsD Protein

Some aspects of this disclosure provide IdsD protein comprising an amino acid sequence as provided by SEQ ID NO:2 or SEQ ID NO:4, or a fragment thereof, wherein the IdsD protein comprises a variable region that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of IdsD protein as provided by SEQ ID NO:10 or SEQ ID NO:12, and wherein the amino acid sequence of the IdsD protein is not identical to the amino acid sequence of a naturally occurring Proteus mirabilis IdsD protein.

In some embodiments, the IdsD protein is a fragment comprising the variable region. In some embodiments, the IdsD protein fragment is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the IdsD variable region from P. mirabilis strain BB2000 corresponding to SEQ ID NO:2 (underline: variable region) or SEQ ID NO:10. In some embodiments, the IdsD protein fragment is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the IdsD variable region from P. mirabilis strain HI4320 corresponding to SEQ ID NO:4 (underline: variable region) or SEQ ID NO:12.

In some embodiments, the variable region comprises one or more mutations. In some embodiments, the one or more mutations is at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least fifteen, at least twenty, or at least twenty five mutations in the variable region. In some embodiments, the one or more mutations are mutations to amino acid residues 761 and/or 765 of amino acid sequences provided by SEQ ID NO:2 or SEQ ID NO:4. In some embodiments, the one or more mutations are mutations to amino acid residues 1 and/or 5 of amino acid sequences provided by SEQ ID NO:10 or SEQ ID NO:12.

In some embodiments, the IdsD protein is a recombinant IdsD protein. In some embodiments, the IdsD protein is an IdsD fusion protein. In some embodiments, the IdsD fusion protein is formed, for example, by an in-frame gene fusion to result in the expression of IdsD protein or polypeptide fragment thereof fused to a second polypeptide, such as an affinity tag for purification or identification, a fluorescent polypeptide for in situ visualization of the fusion protein, or any polypeptides that promote bacterial uptake of the fusion protein.

In some embodiments, the IdsD protein may comprise one or more distinct amino acid sequences. For example, the IdsD protein may comprise a mixture of IdsD protein having sequence similarity to IdsD protein from P. mirabilis strain BB2000 and IdsD protein having sequence similarity to IdsD protein from P. mirabilis strain HI4320.

Some aspects of this disclosure provide IdsD protein in a therapeutically effective amount. In some embodiments, a therapeutically effective amount of IdsD protein as provided herein may vary depending upon known factors such as use and length of use, pharmaceutical characteristics of the composition, and age, sex, weight, and health of the subject. In some embodiments, the therapeutically effective amount of IdsD protein is between 0.1 and 0.5 mg. In some embodiments, the therapeutically effective amount of IdsD protein is between 0.5 and 1 mg. In some embodiments, the therapeutically effective amount of IdsD protein is between 1 and 10 mg.

In some aspects of this disclosure, IdsD protein is provided by nucleic acids. In some embodiments, the nucleic acids encoding the IdsD protein are provided by SEQ ID NO:1 or SEQ ID NO:3. In some embodiments, the nucleic acids encoding the IdsD protein are provided by SEQ ID NO:9 or SEQ ID NO:11. In some embodiments, the nucleic acid encoding IdsD protein is a vector that renders a bacteria capable of expressing IdsD protein. In some embodiments, the nucleic acid encoding IdsD protein is DNA. In some embodiments, the nucleic acid encoding IdsD protein is RNA.

In some aspects of this disclosure, IdsD protein is provided by a bacterial composition secreting IdsD protein. In some embodiments, the bacterial composition comprises a non-pathogenic bacteria. In some embodiments, the bacterial composition comprises Proteus mirabilis.

In some embodiments, a bacterial composition secreting IdsD protein is coated onto a surface. In some embodiments, the surface is coated with between 10² and 10³ colony forming units per centimeter of surface. In some embodiments, the surface is coated with between 10³ and 10⁴ colony forming units per centimeter of surface. In some embodiments, the surface is coated with between 10⁴ and 10⁵ colony forming units per centimeter of surface.

In some embodiments, the bacteria composition comprises viable whole cells of the bacteria. In some embodiments, the bacteria composition comprises non-viable whole cells or cellular extracts of the bacteria. In some embodiments, the bacteria composition comprises viable whole cells and non-viable whole cells or cellular extracts of the bacteria. In some embodiments, the bacteria composition comprises two or more types of bacteria.

In some aspects of this disclosure, IdsD protein is provided by a pharmaceutical composition comprising the IdsD protein and a pharmaceutically acceptable carrier. In some embodiments, the IdsD protein further comprises one or more therapeutic agents. In some embodiments, the therapeutic agent is an antibiotic.

Pharmaceutical Compositions

The present invention provides pharmaceutical compositions comprising P. mirabilis IdsD for use in inhibiting bacterial growth and/or swarming. Pharmaceutical compositions may comprise any suitable P. mirabilis IdsD compositions as provided herein. In some embodiments, the pharmaceutical composition comprises P. mirabilis IdsD protein. In some embodiments, the pharmaceutical composition comprises nucleic acids encoding P. mirabilis IdsD. In some embodiments, the pharmaceutical composition comprises a bacterial composition that secretes P. mirabilis IdsD. In some embodiments, the pharmaceutical composition comprises a pharmaceutical composition comprising P. mirabilis IdsD.

In some embodiments, the pharmaceutical composition is coated onto a medical device. In some embodiments, the pharmaceutical composition is for use in preventing and/or treating a bacterial infection. In some embodiments, the pharmaceutical composition is for use in preventing and/or treating a urinary tract infection. In some embodiments, the pharmaceutical composition is for use in preventing and/or treating a catheter-associated urinary tract infection.

In some embodiments, P. mirabilis IdsD is provided in an effective amount in the pharmaceutical composition. In some embodiments, the effective amount is effective for preventing and/or treating a bacterial infection in a subject in need thereof. In some embodiments, the effective amount is effective for preventing and/or treating a urinary tract infection in a subject in need thereof. In some embodiments, the effective amount is effective for preventing and/or treating a catheter-associated urinary tract infection in a subject in need thereof. In some embodiments, the effective amount is effective for preventing and/or reducing bacterial growth. In some embodiments, the effective amount is effective for preventing and/or reducing bacterial swarming. In some embodiments, the effective amount is a therapeutically effective amount. In some embodiments, the effective amount is a prophylactically effective amount.

The pharmaceutical compositions described herein may be useful in preventing and/or treating bacterial infection in a subject. In some embodiments, the bacterial infection is a Proteus mirabilis infection. In some embodiments, the bacterial infection is a gram-negative bacterial infection. Examples of gram-negative bacteria that may infect a subject include, but are not limited to, Escherichia, Shigella, Edwardsiella, Salmonella, Citrobacter, Klebsiella, Enterobacter, Hafnia, Serratia, Morganella, Providencia, Yersinia, Erwinia, Buttlauxella, Cedecea, Ewingella, Kluyvera, Tatumella, Rahnella, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia, Cepacia, Gardenerella, Vaginalis, or Acinetobacter. In some embodiments, the bacterial infection is a gram-positive bacterial infection. Examples of gram-negative bacteria that may infect a subject include, but are not limited to, Staphylococcus, Streptococci, Enterococci, Corynebacteria, and Bacillus species.

It will also be appreciated that the compositions described herein can be employed in combination therapies, that is, the compositions or pharmaceutical compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder, or they may achieve different effects (e.g., control of any adverse effects).

In addition to P. mirabilis IdsD, the pharmaceutical composition described herein may comprise one or more additional pharmaceutical agents. In some embodiments, the additional pharmaceutical agent is an antimicrobial including, but not limited to, an antibiotic, an antifungal, or an antiviral.

Examples of antibiotics include, but are not limited to penicillins, cephalosporins, carbepenems, other beta-lactams antibiotics, aminoglycosides, macrolides, lincosamides, glycopeptides, tetracylines, chloramphenicol, quinolones, fucidins, sulfonamides, trimethoprims, rifamycins, oxalines, streptogramins, lipopeptides, ketolides, polyenes, azoles, and echinocandins.

Examples of antifungals include, but are not limited to, polyene antifungals—natamycin, rimocidin, filipin, nystatin, amphotericin B, candicin, and hamycin; imidazole antifungals—miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, and tioconazole; triazole antifungals—fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole, and albaconazole; thiazole antifungals—abafungin; allylamine antifungals—terbinafine, naftifine, and butenafine; and echinocandin antifungals—anidulafungin, caspofungin, and micafungin. Other compounds that have antifungal properties include, but are not limited to polygodial, benzoic acid, ciclopirox, tolnaftate, undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin, and haloprogin.

Examples of antivirals include, but are not limited to, Abacavir, Acyclovir, Adefovir, Amprenavir, Atazanavir, Cidofovir, Darunavir, Delavirdine, Didanosine, Docosanol, Efavirenz, Elvitegravir, Emtricitabine, Enfuvirtide, Etravirine, Famciclovir, Foscarnet, Fomivirsen, Ganciclovir, Indinavir, Idoxuridine, Lamivudine, Lopinavir Maraviroc, MK-2048, Nelfinavir, Nevirapine, Penciclovir, Raltegravir, Rilpivirine, Ritonavir, Saquinavir, Stavudine, Tenofovir Trifluridine, Valaciclovir, Valganciclovir, Vidarabine, Ibacitabine, Amantadine, Oseltamivir, Rimantidine, Tipranavir, Zalcitabine, Zanamivir and Zidovudine.

In some embodiments, the compound or pharmaceutical composition is a solid. In some embodiments, the compound or pharmaceutical composition is a powder. In some embodiments, the compound or pharmaceutical composition can be dissolved in a liquid to make a solution. In some embodiments, the compound or pharmaceutical composition is dissolved in water to make an aqueous solution. In some embodiments, the pharmaceutical composition is a liquid for topical administration (e.g., skin of a subject in need thereof). In some embodiments, the pharmaceutical composition is a liquid for coating a medical device (e.g., catheter). In some embodiments, the pharmaceutical composition is a liquid for oral administration (e.g., ingestion). In some embodiments, the pharmaceutical composition is a liquid for parental injection. In some embodiments, the pharmaceutical composition is a liquid (e.g., aqueous solution) for intravenous injection. In some embodiments, the pharmaceutical composition is a liquid (e.g., aqueous solution) for subcutaneous injection.

After formulation with an appropriate pharmaceutically acceptable excipient in a desired dosage, the pharmaceutical compositions of this invention can be administered to humans and other animals orally, parenterally, intracisternally, intraperitoneally, topically, bucally, or the like, depending on the disease or condition being treated. In some embodiments, a pharmaceutical composition comprising IdsD protein is administered, orally or parenterally, at dosage levels of each pharmaceutical composition sufficient to deliver from about 0.001 mg/kg to about 200 mg/kg in one or more dose administrations for one or several days (depending on the mode of administration).

In some embodiments, the effective amount per dose varies from about 0.001 mg/kg to about 200 mg/kg, about 0.001 mg/kg to about 100 mg/kg, about 0.01 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, preferably from about 0.1 mg/kg to about 40 mg/kg, preferably from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic and/or prophylactic effect. In some embodiments, the compounds described herein may be at dosage levels sufficient to deliver from about 0.001 mg/kg to about 200 mg/kg, from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, preferably from about 0.1 mg/kg to about 40 mg/kg, preferably from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, and more preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic and/or prophylactic effect. The desired dosage may be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In some embodiments, the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations). In some embodiments, each composition described herein is administered at a dose that is below the dose at which the agent causes non-specific effects.

In some embodiments, the pharmaceutical composition is administered at a dose of about 0.001 mg to about 200 mg a day. In some embodiments, the pharmaceutical composition is administered at a dose of about 0.01 mg to about 100 mg a day. In some embodiments, pharmaceutical composition is administered at a dose of about 0.01 mg to about 50 mg a day. In some embodiments, the pharmaceutical composition is administered at a dose of about 0.01 mg to about 10 mg a day. In some embodiments, the pharmaceutical composition is administered at a dose of about 0.1 mg to about 10 mg a day.

Pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include the steps of bringing the composition comprising IdsD protein, into association with a carrier and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.

Pharmaceutical compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a “unit dose” is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage, such as, for example, one-half or one-third of such a dosage.

Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) active ingredient.

Pharmaceutically acceptable excipients used in the manufacture of provided pharmaceutical compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition.

Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.

Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.

Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate (Tween 20), polyoxyethylene sorbitan (Tween 60), polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monopalmitate (Span 40), sorbitan monostearate (Span 60), sorbitan tristearate (Span 65), glyceryl monooleate, sorbitan monooleate (Span 80)), polyoxyethylene esters (e.g. polyoxyethylene monostearate (Myrj 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. Cremophor™), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether (Brij 30)), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F-68, Poloxamer-188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and/or mixtures thereof.

Exemplary binding agents include starch (e.g. cornstarch and starch paste), gelatin, sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g. acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, and/or mixtures thereof.

Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives. In certain embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent.

Exemplary antioxidants include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.

Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.

Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.

Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.

Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.

Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, and Euxyl.

Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and mixtures thereof.

Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.

Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof.

Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active agents, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. In certain embodiments for parenteral administration, agents of the invention are mixed with solubilizing agents such CREMOPHOR EL® (polyethoxylated castor oil), alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and combinations thereof.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active agent is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The active agents can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active agent may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

Formulations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments, or pastes; or solutions or suspensions such as drops. Formulations for topical administration to the skin surface can be prepared by dispersing the drug with a dermatologically acceptable carrier such as a lotion, cream, ointment, or soap. Useful carriers are capable of forming a film or layer over the skin to localize application and inhibit removal. For topical administration to internal tissue surfaces, the agent can be dispersed in a liquid tissue adhesive or other substance known to enhance adsorption to a tissue surface. For example, hydroxypropylcellulose or fibrinogen/thrombin solutions can be used to advantage. Alternatively, tissue-coating solutions, such as pectin-containing formulations can be used. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of an agent to the body. Such dosage forms can be made by dissolving or dispensing the agent in the proper medium. Absorption enhancers can also be used to increase the flux of the agent across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the agent in a polymer matrix or gel.

Additionally, the carrier for a topical formulation can be in the form of a hydroalcoholic system (e.g., quids and gels), an anhydrous oil or silicone based system, or an emulsion system, including, but not limited to, oil-in-water, water-in-oil, water-in-oil-in-water, and oil-in-water-in-silicone emulsions. The emulsions can cover a broad range of consistencies including thin lotions (which can also be suitable for spray or aerosol delivery), creamy lotions, light creams, heavy creams, and the like. The emulsions can also include microemulsion systems. Other suitable topical carriers include anhydrous solids and semisolids (such as gels and sticks); and aqueous based mousse systems.

Methods of Coating a Surface

In one aspect, the present disclosure provides IdsD protein for use in inhibiting bacterial growth and/or swarming on a surface. In some embodiments, the IdsD protein is coated onto a surface that may be prone to bacterial contamination. In some embodiments, the IdsD protein is coated onto a surface contaminated by a bacteria. In some embodiments, the IdsD protein is applied prophylactically over a “clean” surface that is not contaminated by bacteria.

In some embodiments, the IdsD protein is coated onto a medical device. Exemplary medical devices include, but are not limited to, catheters such as urinary catheters, venous catheters, arterial catheters, dialysis catheters, peritoneal catheters, urinary sphincters, urinary dilators, urinary stents, tissue bonding urinary devices, vascular grafts, vascular dilators, extravascular dilators, vascular stents, extravascular stents, wound drain tubes, shunts, pacemaker systems, joint replacements, heart valves, cardiac assist valves, bone prosthesis, joint prosthesis, or dental prosthesis.

The area of a surface coated by IdsD protein should be sufficient for inhibiting bacterial growth and/or swarming on the surface. In some embodiments, the IdsD protein is coated on at least a part of the surface. In some embodiments, the IdsD protein is coated on at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 99.5% of the surface.

Any suitable IdsD protein for use in inhibiting bacterial growth and/or swarming on a surface may be coated onto the surface. In some embodiments, the IdsD protein is a liquid. In some embodiments, the IdsD protein is a powder. In some embodiments, the IdsD protein can be dissolved in a liquid to make a solution. In some embodiments, the IdsD protein-containing liquid can be a solution, a suspension, a colloid, or a dispersion.

Any method suitable for coating IdsD protein onto a surface may be used. In some embodiments, coating IdsD protein onto a surface comprises spraying IdsD protein onto the surface. In some embodiments, coating IdsD protein onto a surface comprises brushing IdsD protein onto the surface. In some embodiments, coating IdsD protein onto a surface comprises applying IdsD protein onto the surface. In some embodiments, coating IdsD protein onto a surface comprises treating IdsD protein onto the surface.

Any amount of IdsD protein suitable for inhibiting bacterial growth and/or swarming on a surface may be used. In some embodiments, the surface has between 0.1 and 1.0 mg of IdsD protein per cm² of surface area. In some embodiments, the surface has between 1 and 10 mg of IdsD protein per cm² of surface area. In some embodiments, the surface has between 10 and 100 mg of IdsD protein per cm² of surface area.

Any thickness of IdsD protein coating that does not altering the functionality of a surface may be coated onto the surface. In some embodiments, the IdsD protein coating is between about 0.0001 millimeters and 10 millimeters in thickness. In some embodiments, the IdsD protein coating is between 0.5 and about 5 millimeters in thickness. In some embodiments, the IdsD protein coating is between 1 and about 4 millimeters in thickness.

Methods of Preventing and/or Treating a Bacterial Infection

In one aspect, the present disclosure provides methods for preventing and treating bacterial infections in a subject using IdsD protein. In some embodiments, the bacterial infection is a Proteus mirabilis infection. In some embodiments, the bacterial infection is caused by a Gram-positive bacterium. Exemplary Gram-positive bacteria include, but are not limited to, species of the genera Staphylococcus, Streptococcus, Micrococcus, Peptococcus, Peptostreptococcus, Enterococcus, Bacillus, Clostridium, Lactobacillus, Listeria, Erysipelothrix, Propionibacterium, Eubacterium, and Corynebacterium. In some embodiments, the Gram-positive bacterium is a bacterium of the phylum Firmicutes. In some embodiments, the bacterium is a member of the phylum Firmicutes and the genus Enterococcus, i.e., the bacterial infection is an Enterococcus infection. Exemplary Enterococci bacteria include, but are not limited to, E. avium, E. durans, E. faecalis, E. faecium, E. gallinarum, E. solitarius, E. casseliflavus, and E. raffinosus. In some embodiments, the Enterococcus infection is an E. faecalis infection. In some embodiments, the Enterococcus infection is an E. faecium infection. In some embodiments, the bacteria is a member of the phylum Firmicutes and the genus Staphylococcus, i.e., the bacterial infection is a Staphylococcus infection. Exemplary Staphylococci bacteria include, but are not limited to, S. arlettae, S. aureus, S. auricularis, S. capitis, S. caprae, S. carnous, S. chromogenes, S. cohii, S. condimenti, S. croceolyticus, S. delphini, S. devriesei, S. epidermis, S. equorum, S. felis, S. fluroettii, S. gallinarum, S. haemolyticus, S. hominis, S. hyicus, S. intermedius, S. kloosii, S. leei, S. lenus, S. lugdunesis, S. lutrae, S. lyticans, S. massiliensis, S. microti, S. muscae, S. nepalensis, S. pasteuri, S. penttenkoferi, S. piscifermentans, S. psuedointermedius, S. psudolugdensis, S. pulvereri, S. rostri, S. saccharolyticus, S. saprophyticus, S. schleiferi, S. sciuri, S. simiae, S. simulans, S. stepanovicii, S. succinus, S. vitulinus, S. warneri, and S. xylosus. In some embodiments, the Staphylococcus infection is an S. aureus infection. In some embodiments, the Staphylococcus infection is an S. epidermis infection. In some embodiments, the Gram-positive bacterium is selected from the group consisting of Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus capitis, Staphylococcus cohnii, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdanensis, Staphylococcus saccharolyticus, Staphylococcus saprophyticus, Staphylococcus schleiferi, Staphylococcus similans, Staphylococcus warneri, Staphylococcus xylosus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus bovis, Streptococcus canis, Streptococcus equi, Streptococcus milleri, Streptococcus mitior, Streptococcus mutans, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus salivarius, Streptococcus sanguis, Bacillus anthracis, Clostridium botulinum, Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheriae, Corynebacterium jeikeium, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Gardnerella vaginalis, Gemella morbillorum, Mycobacterium abcessus, Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium haemophilium, Mycobacterium kansasii, Mycobacterium leprae, Mycobacterium marinum, Mycobacterium scrofulaceum, Mycobacterium smegmatis, Mycobacterium terrae, Mycobacterium tuberculosis, Mycobacterium ulcerans, and Peptococcus niger.

In some embodiments, the bacterial infection being treated and/or prevented is an infection caused by a Gram-negative bacterium. Exemplary Gram-negative bacteria include, but are not limited to, Escherchia coli, Caulobacter crescentus, Pseudomonas, Agrobacterium tumefaciens, Branhamella catarrhalis, Citrobacter diversus, Enterobacter aerogenes, Klebsiella pneumoniae, Proteus mirabilis, Salmonella typhimurium, Neisseria meningitidis, Serratia marcescens, Shigella sonnei, Neisseria gonorrhoeae, Acinetobacter baumannii, Salmonella enteriditis, Fusobacterium nucleatum, Veillonella parvula, Bacteroides forsythus, Actinobacillus actinomycetemcomitans, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Helicobacter pylori, Francisella tularensis, Yersinia pestis, Morganella morganii, Edwardsiella tarda, and Haemophilus influenzae. In certain embodiments, the Gram-negative bacteria species is Pseudomonas. In certain embodiments, the Gram-negative bacteria species is Pseudomonas aeruginosa.

In some embodiments, the bacterial infection being treated and/or prevented is a urinary tract infection (most commonly caused by Escherichia coli, Proteus mirabilis, and/or Staphylococcus saprophyticus). In some embodiments, the bacterial infection is a catheter-associated urinary tract infection. In some embodiments, the bacterial infection is gastritis (most commonly caused by Helicobacter pylori), respiratory infection (such as those commonly afflicting patents with cystic fibrosis, most commonly caused by Pseudomonas aeuroginosa), cystitis (most commonly caused by Escherichia coli), pyelonephritis (most commonly caused by Proteus species, Escherichia coli and/or Pseudomonas sp), osteomyelitis (most commonly caused by Staphylococcus aureus, but also by Escherichia coli), bacteremia, skin infection, rosacea, acne, chronic wound infection, infectious kidney stones (can be caused by Proteus mirabilis), bacterial endocarditis, and/or sinus infection.

In some embodiments, the bacterial infection being treated and/or prevented is caused by an organism resistant to one or more antibiotics. For example, in some embodiments, the bacterial infection is caused by an organism resistant to penicillin. In some embodiments, the bacterial infection is caused by an organism resistant to vancomycin (VR). In some embodiments, the bacterial infection is caused by vancomycin-resistant E. faecalis. In some embodiments, the bacterial infection is caused by vancomycin-resistant E. faecium. In some embodiments, the bacterial infection is caused by vancomycin-resistant Staphylococcus aureus (VRSA). In some embodiments, the bacterial infection is caused by vancomycin-resistant Enterococci (VRE). In some embodiments, the bacterial infection is caused by a methicillin-resistant (MR) organism. In some embodiments, the bacterial infection is caused by methicillin-resistant S. aureus (MRSA). In some embodiments, the bacterial infection is caused by methicillin-resistant Staphylococcus epidermidis (MRSE). In some embodiments, the bacterial infection is caused by penicillin-resistant Streptococcus pneumonia. In some embodiments, the bacterial infection is caused by quinolone-resistant Staphylococcus aureus (QRSA). In some embodiments, the bacterial infection is caused by multi-drug resistant Mycobacterium tuberculosis.

In some embodiments, the subject administered the IdsD protein or pharmaceutical composition as provided herein is a mammal. In some embodiments, the subject is a human. In certain embodiments, the subject is an immunocompromised subject. In some embodiments, the subject is a domesticated animal, such as a dog, cat, cow, pig, horse, sheep, or goat. In some embodiments, the subject is a companion animal such as a dog or cat. In some embodiments, the subject is a livestock animal such as a cow, pig, horse, sheep, or goat. In some embodiments, the subject is a zoo animal. In another embodiment, the subject is an experimental animal such as a rodent or non-human primate.

The IdsD protein or pharmaceutical composition can be administered concurrently with, prior to, or subsequent to, one or more additional therapeutically active agents (e.g., antibiotics, anti-inflammatory agents). In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. In will further be appreciated that the additional therapeutically active agent utilized in this combination can be administered together in a single composition or administered separately in different compositions. The particular combination to employ in a regimen will take into account compatibility of the inventive compound with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved. In general, it is expected that additional therapeutically active agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.

In some embodiments, the subject is administered IdsD protein and one or more additional therapeutic agents. In some embodiments, the additional therapeutic agent is an antimicrobial including, but not limited to, an antibiotic, an antifungal, or an antiviral.

Examples of antibiotics include, but are not limited to penicillins, cephalosporins, carbepenems, other beta-lactams antibiotics, aminoglycosides, macrolides, lincosamides, glycopeptides, tetracylines, chloramphenicol, quinolones, fucidins, sulfonamides, trimethoprims, rifamycins, oxalines, streptogramins, lipopeptides, ketolides, polyenes, azoles, and echinocandins.

Examples of antifungals include, but are not limited to, polyene antifungals—natamycin, rimocidin, filipin, nystatin, amphotericin B, candicin, and hamycin; imidazole antifungals—miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, and tioconazole; triazole antifungals—fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole, and albaconazole; thiazole antifungals—abafungin; allylamine antifungals—terbinafine, naftifine, and butenafine; and echinocandin antifungals—anidulafungin, caspofungin, and micafungin. Other compounds that have antifungal properties include, but are not limited to polygodial, benzoic acid, ciclopirox, tolnaftate, undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin, and haloprogin.

Examples of antivirals include, but are not limited to, Abacavir, Acyclovir, Adefovir, Amprenavir, Atazanavir, Cidofovir, Darunavir, Delavirdine, Didanosine, Docosanol, Efavirenz, Elvitegravir, Emtricitabine, Enfuvirtide, Etravirine, Famciclovir, Foscarnet, Fomivirsen, Ganciclovir, Indinavir, Idoxuridine, Lamivudine, Lopinavir Maraviroc, MK-2048, Nelfinavir, Nevirapine, Penciclovir, Raltegravir, Rilpivirine, Ritonavir, Saquinavir, Stavudine, Tenofovir Trifluridine, Valaciclovir, Valganciclovir, Vidarabine, Ibacitabine, Amantadine, Oseltamivir, Rimantidine, Tipranavir, Zalcitabine, Zanamivir and Zidovudine.

Kits

A medical device kit comprises a medical device and IdsD protein. In some embodiments, the medical device kit comprises a medical device that is pre-coated with a therapeutically effective amount of IdsD protein. In some embodiments, the medical device kit comprises a medical device and a therapeutically effective amount of IdsD protein that can be coated onto the surface of the medical device by a health care practitioner.

A medical device kit may comprise any suitable form of IdsD protein. In some embodiments, the IdsD protein is recombinant IdsD protein. In some embodiments, the IdsD protein is nucleic acids encoding the IdsD protein. In some embodiments, the IdsD protein is supplied by a bacterial composition that makes and/or secretes the IdsD protein. In some embodiments, the IdsD protein is a pharmaceutical composition.

The present disclosure encompasses a medical device kit comprising any medical device suitable for coating with IdsD protein. Exemplary medical devices include, but are not limited to, catheters such as urinary catheters, venous catheters, arterial catheters, dialysis catheters, peritoneal catheters, urinary sphincters, urinary dilators, urinary stents, tissue bonding urinary devices, vascular grafts, vascular dilators, extravascular dilators, vascular stents, extravascular stents, wound drain tubes, shunts, pacemaker systems, joint replacements, heart valves, cardiac assist valves, bone prosthesis, joint prosthesis, or dental prosthesis.

EXAMPLES

The following Examples are intended to illustrate and to describe particular embodiments, but are not intended to exemplify the full scope of the invention. Accordingly, it will be understood that the Examples are not meant to limit the scope of the invention.

Example 1: Non-Cognate IdsD-IdsE Pairs Cause Restricted Swarm Colony Expansion but not Reduced Viability or Apparent Swarmer Cell Differentiation

Swarming colonies of P. mirabilis strain BB2000 carrying mutations in the variable regions (VRs) encoded by the ids operon appear unusually small in diameter (31). To investigate effects of Ids-mediated self-recognition on swarm colony expansion, these P. mirabilis strains, which are genetically identical except for the VRs in IdsD and IdsE, were utilized. The VRs either originated from wild-type strain BB2000 (VR-BB) or from wild-type strain HI4320 (VR-HI). The ids operon, including the genes for IdsD and IdsE, was maintained on a low-copy number plasmid under control of the native promoter in the/lids strain, which is a BB2000-derived strain lacking the chromosomal copy of the ids locus (2). This complemented Aids strain and its derivatives are the standard tools for studying the Ids system (2, 5, 31).

To determine the cellular locations of IdsD and IdsE, subcellular fractions of swarming BB2000 were prepared and the presence of IdsD, IdsE, and σ⁷⁰ was detected by Western blotting. Whole cell extract of Aids was prepared as a control. A band corresponding to σ⁷⁰ was seen in all fractions (FIG. 6). No bands corresponding to IdsD or IdsE were observed in the cytoplasmic fraction (FIG. 6). These results indicate that IdsD and IdsE are localized to the cell envelope in P. mirabilis strain BB2000.

After 16 hours on swarm-permissive agar, swarm colonies of a strain producing the cognate D_(VR-BB)E_(VR-BB) pair (CCS01) expanded significantly further than swarm colonies of strains producing the non-cognate D_(VR-HI)E_(VR-BB) (CCS02) or D_(VR-BB)E_(VR-HI) (CCS03) pairs (FIG. 1A). In contrast, a strain producing the cognate D_(VR-HI)E_(VR-HI) pair (CCSO4) showed recovered swarm expansion (FIG. 1A). Differences in colony expansion persisted even after 24 hours (FIG. 1B). Thus, colony swarm expansion was restricted when non-cognate IdsD and IdsE proteins are present. However, IdsD and IdsE are not essential for swarming (FIG. 4).

Whether IdsD and IdsE contained cognate or non-cognate variable regions, however, had no measurable effect on the number of swarm rings per colony (FIG. 1A), on growth on surfaces (FIG. 1C and FIG. 5A), or growth in liquid (FIG. 5B), suggesting that growth and swarm-related developmental cycles were not impaired. No significant differences in colony expansion during swimming in low-percentage agar were observed between any of these strains either (FIG. 1D), and individual cells of all four strains were capable of differentiating into elongated, actively moving swarmer cells (data not shown). Therefore, non-cognate IdsD-IdsE pairs do not appear to inhibit cell viability, swimming motility, or swarm colony development; nevertheless, macroscopic colony swarm expansion was impaired. This stark phenotype may be used to address the outstanding question of how the Ids system communicates identity information between cells within a colony.

Example 2: IdsD Communicates Identity Between Neighboring Cells

There are two prevailing mechanistic models for where the causative in vivo interactions between IdsD and IdsE may occur. IdsD and IdsE binding could happen between neighboring cells (FIG. 2A, left panel) or within a single cell (FIG. 2A, right panel). To distinguish between these models, whether IdsD export is necessary for its function was examined. The Aids-derived strain deficient in T6SS-mediated transport (CCS05) was used. CCS05 carries a mutation in vipA; the encoded protein, VipA [T6SS_VipA (PF05591)], is essential for export of T6SS-related factors (11, 33, 34). To confirm loss of T6SS mediated transport, IdsA [T6SS_Hcp (PF05638)] carrying a C-terminal FLAG epitope tag (5) was introduced into CCS05. Export of Hcp homologs, such as IdsA, is a hallmark of T6SS dependent protein transport and has often been used to evaluate T6SS activity (5, 8, 9, 11, 26, 35). Further, the export of IdsD is dependent on a functional T6SS and is correlated with IdsA export (5).

The export of IdsA-FLAG from the CCS05-derived strain was markedly decreased as compared to that from the otherwise genetically equivalent strain expressing wild-type vipA (FIG. 2B). Supernatants isolated from these strains were analyzed by LC-MS/MS. Peptides corresponding to IdsB and IdsD were absent in the CCS05-derived strain expressing mutant vipA and found in the Aids mutant-derived strain expressing wild-type vipA (Table 1). These results indicate that CCS05 is deficient in T6SS-mediated export, including the loss of IdsA, IdsB, and IdsD transport.

TABLE 1 LC-MS/MS results for supernatant fractions, from ~70 to 150 kDa. Predicted No. of No. of size unique total Coverage Strain Protein (kDa) peptides peptides (%) Δids strain σ⁷⁰ 71.11 3 3 4.05 carrying pLMW101 IdsB 81.55 5 5 10.65 (export active) IdsD 118.16 2 6 2.32 CCS05 carrying σ⁷⁰ 71.11 2 2 2.91 pLMW101 (export inactive)

CCS05-derived strains expressing different combinations of IdsD and IdsE variants, were utilized as indicator strains to determine whether IdsD is received from a neighboring cell. Boundary formation phenotypes were determined of these CCS05-derived strains when swarmed against Δids-derived (export-active donor) strains that produced IdsD and IdsE proteins either from strain BB2000 (D_(VR-BB)E_(VR-BB)) or from strain HI4320 (D_(HI)E_(HI)). These two export active strains form a boundary against each other and are non-self (31). Swarming populations of the CCS05-derived strains producing E_(VR-BB) (and either D_(VR-BB) or D_(VR-HI)) merged with the donor strain producing D_(VR-BB)E_(VR-BB) and not with the donor strain producing D_(HI)E_(HI) (FIG. 2C). Conversely, CCS05-derived strains producing E_(VR-HI) (and either D_(VR-BB) or D_(VR-HI)) merged with the donor strain producing D_(HI)E_(HI) (FIG. 2C). In all cases, the IdsD variant produced by the CCS05-derived, export-inactive strain did not affect the outcome (FIG. 2C). Thus, the identities of the IdsD variant in the donor strain and of the IdsE variant in the export-inactive CCS05-derived strain correlated with whether populations merged or formed a boundary.

Given these data, the observed impairment in swarm colony expansion of CCS02 and CCS03, which are the strains producing non-cognate IdsD and IdsE proteins (FIG. 1A), could be explained by the presence of unbound IdsD in recipient cells (FIG. 2A, left panel). If so, then a similar defect would be expected for strains lacking IdsE since, in a clonal population, every cell could export as well as receive IdsD and would have no IdsE to bind it. Therefore, a Δids-derived strain complemented with an ids operon that lacks the gene encoding IdsE (CCS06) was constructed to test this hypothesis.

CCS06 swarms displayed colony expansion similar to that of CCS02 and CCS03 (FIG. 3A). CCS06 did not exhibit defects in swarm rings per colony (FIG. 3A), growth on surfaces (FIG. 5A), or growth in liquid (FIG. 5B). Therefore, the presence of unbound IdsD indeed impaired swarm colony expansion.

The question remained, however, whether IdsD exchange between cells is crucial for this swarm inhibition or whether unbound, self-produced IdsD could also affect self-recognition behaviors. Therefore, the swarm colony expansion of export-inactive, CCS05-derived cells lacking IdsE was examined. In this strain, cells contain self-produced IdsD but cannot export IdsD, i.e., cells do not contain a transferred IdsD. This strain exhibited a rescued swarm colony expansion phenotype (FIG. 3A). Together these results support the hypothesis that IdsD is exported and that it is transferred between cells (FIG. 2A, left panel). Moreover, transferred, unbound IdsD in recipient cells, rather than self-produced IdsD, appears to impair swarm colony expansion.

Example 3: Interactions Between Transferred IdsD and Resident IdsE Impact Swarm Colony Expansion

It was hypothesized that the transfer of IdsD might be sufficient to induce impaired swarm colony expansion. This hypothesis was interrogated by examining the swarm colony expansion of 1:1 mixtures of two strains, resulting in co-swarms. Strain CCS06 (lacking IdsE) was co-swarmed with the nearly isogenic CCS05-derived recipient strain lacking both IdsE and a functional T6SS. A 1.75-fold decrease in expansion of the co-swarm colony as compared to that of a monoculture swarm of the recipient strain (FIG. 3A) was observed. These results indicate that transfer of IdsD to recipient cells restricted swarm colony expansion.

It was further hypothesized that transfer of IdsD and its resulting binding state with IdsE in the recipient cell determines whether swarm colony expansion is restricted or not. Therefore, CCS06 as a donor of D_(VR-BB) was used in 1:1 mixtures with CCS05-derived (export-inactive recipient) strains that produced either E_(VR-BB), which binds D_(VR-BB), or E_(VR-HI), which cannot bind D_(VR-BB). All co-swarms were compared to monoculture swarms of the recipient strain. In coswarms of CCS06 with the recipient strain producing D_(VR-BB) and E_(VR-HI), a 3.12-fold reduction was observed (FIGS. 3A-3B). Likewise, a coswarm of CCS06 with the recipient strain producing D_(VR-HI) and E_(VR-HI) resulted in a 3.35-fold reduction in colony expansion (FIGS. 3A-3B). By contrast, mixing CCS06 with the recipient strain producing D_(VR-BB) and E_(VR-BB) resulted in a non-significant reduction in colony expansion (FIGS. 3A-3B). In sum, no restriction appeared when the IdsE variant in the recipient strain is capable of binding D_(VR-BB) from the donor strain. However, we observed a ˜2-3 fold restriction in swarm colony expansion when IdsE in the recipient strain is non-cognate to D_(VR-BB). Thus, communication of IdsD from a donor to a recipient cell causes restricted swarm colony expansion. Alleviation of this swarm restriction can be achieved by the presence of a cognate IdsE in the recipient cell.

During the course of observing monoclonal swarms, it was unexpectedly noticed that the production of IdsE in recipient strains, regardless of whether a cognate IdsD was produced, resulted in a marked decrease of colony expansion (average=2.3-fold) as compared to that for an otherwise identical strain that lacked IdsE (FIG. 3A). These results raise the possibility that independently of IdsD, IdsE itself contributes to repression of swarm colony expansion.

Discussion.

Disclosed herein are results that address unresolved questions regarding the communication of Ids proteins within a colony of swarming P. mirabilis. The results provided herein have shown that the self-identity protein IdsD is communicated from one cell to another. Also provided herein is evidence that IdsD from donor cells likely interacts with IdsE in recipient cells and that lack of this interaction negatively impacts swarm colony expansion, but not viability. Therefore, IdsD might represent a class of non-lethal T6SS effector proteins.

Based on the prominent T6SS models for effector/inhibitor pairs, it was expected that unbound IdsD, whether in donor or recipient cells, should suffice to act as an effector. However, this was not strictly observed since unbound IdsD was only active in recipient cells. We hypothesize that one or more proteins in the donor cell might act to sequester IdsD. Alternatively, or in addition to, IdsD might not be in a folded or active state in the donor cell. Even more surprisingly, the presence of IdsE in export-impaired cells appeared to have an inhibitory effect on colony expansion (FIG. 3A). Together our observations suggest that IdsD and IdsE regulate swarm colony expansion. However, the specific molecular mechanisms remain to be determined.

It is a bit perplexing that IdsD is indeed communicated between cells in a T6SS-dependent manner as IdsD is over 100 kDa in size and contains two predicted transmembrane segments (31). Many T6SS-exported effectors are under 50 kDa, and the inner Hcp tube comprising the channel of many T6SSs has a width of 40 Å in multiple bacteria (8, 36-38). In fact, a variety of T6SS effectors bind to the inside of the Hcp tube allowing them to be exported (35). The size of the P. mirabilis T6SS pore has not been directly measured. However given IdsD's large size, IdsD might be communicated via the T6SS by an alternative mechanism. For example, IdsD might be exported out of the donor cell in an unfolded state and then fold into its active state before or after being received by the recipient cell. This would be consistent with the observation that IdsD transfer is required for its activity (FIG. 3A). Clearly, the macromolecular states of IdsD before, during, and after transfer remain to be resolved to explain this transfer.

Microbial communities frequently exhibit cell-to-cell communication, in many cases involving the exchange of information about kin group identity. Self versus non-self recognition allows that certain group behaviors primarily occur between closely related individuals and/or exclude non-kin cells from shared resources. Many of the mechanisms for the exchange of kin group identity can be distinguished based on their contact-dependency or effects on viability. Quorum sensing by which groups of bacteria can roughly assess cell population density is an example of contact-independent recognition. In this case, kin group identity information is encoded by the molecular structure of the quorum sensing molecule and its ability to bind its protein receptor (39-42). However, as quorum sensing molecules are often diffusible across membranes (43, 44), recognition events do not require physical contact between cells and can occur over greater spatial distances than contact-dependent mechanisms.

By contrast, contact-dependent interactions are local. These recognition events usually require cell-to-cell contact and can involve lethal attacks on non-kin members of the community. For example, contact-dependent killing mechanisms have been described for antagonistic interactions between species and even genera, e.g., T6SS-associated killing (8-10, 13, 14, 16-20, 27, 28), and within a species, e.g., contact-dependent inhibition (CDI) (45-52). From a competition perspective this could be beneficial because when susceptible competitor cells are inhibited, fewer cells will compete for resources like nutrients. However, the existence of contact dependent recognition that does not involve killing, such as demonstrated here for the self-identity proteins IdsD and IdsE, suggests that there is likely a fitness and competitive advantage to recognizing cells of the same kin group. For P. mirabilis, swarm expansion of the colony involves intimate interactions between individual cells (53), and so cooperation might be essential for long-range motility. One purpose of the Ids system, and specifically of the self-identity proteins, IdsD and IdsE, might be to restrict cooperative motility behavior to kin cells. As such, the transfer of IdsD and its subsequent interactions with IdsE may represent an additional form of cell-cell communication within a bacterial population.

Materials and Methods

Bacterial Strains and Media.

All strains and plasmids are described in the supplemental material (see Table 2). P. mirabilis strains were maintained on LSW⁻ agar (54). CM55 blood agar base agar (Oxoid, Basingstoke, England) was used for swarm-permissive nutrient plates. Overnight cultures of all strains were grown in LB broth under aerobic conditions at 37° C. Kanamycin was used at a concentration of 35 μg/ml for plasmid maintenance and was added to all swarm and growth media.

We employed a previously published ids expression system (2) in which the entire ids locus from P. mirabilis strain BB2000 is expressed from a low-copy number plasmid under control of its native promoter (pIdsBB) in a BB2000-derived strain lacking the chromosomal copy of the ids operon (Δids) (2). We engineered alterations to the ids locus on the vector; hence, all strains are isogenic except for the encoded ids genes.

TABLE 2 Strains used in this disclosure. Strain Name Description Source Notes Proteus mirabilis BB2000 Produces the (59) Wildtype cognate D_(VR-BB)E_(VR-BB) pair from a single allele BB2000::Δids Δids (55) Δids::Tn-Cm(R) Δids c. CCS01 Δids producing the (55) Δids::Tn-Cm(R) carrying plasmid pIdsBB cognate D_(VR-BB)E_(VR-BB) pair pIdsBB containing the entire BB2000 ids operon (idsA-F) under control of its native promoter. This is strain Δids c. pids_(BB2000) in (1) Δids c. CCS02 Δids (60) Δids::Tn-Cm(R) carrying a derivative pIdsBB-D_(VR-HI-) producing the of pIdsBB in which the sequence E_(VR-BB) non-cognate encoding amino acids 761-865 of D_(VR-HI)E_(VR-BB) IdsD has been replaced with the pair equivalent sequence of idsD from strain HI4320 Δids c. CCS03 Δids (60) Δids::Tn-Cm(R) carrying a derivative pIdsBB-D_(VR-HI-) producing the of pIdsBB in which the sequence E_(VR-BB) non-cognate encoding amino acids 147-169 from D_(VR-HI)E_(VR-BB) IdsE has been replaced with the pair equivalent sequence of idsE from strain HI4320 Δids c. CCS04 Δids (60) Δids::Tn-Cm(R) carrying a derivative pIdsBB-D_(VR-HI-) producing the of pIdsBB in which the sequences E_(VR-BB) cognate encoding amino acids 761-865 from D_(VR-HI)E_(VR-BB) IdsD and 147-169 from IdsE have pair been replaced with the equivalent sequences of idsD and idsE, respectively, from strain HI4320. This is vector pIds_(BB-idsD-BB to HI-idsE-BB to HI) in (6) Δids c. (55) Δids::Tn-Cm(R) carrying a pIdsBB-E-mt derivative of pIdsBB in which the 102 bp SacI-AgeI fragment of idsE has been replaced by a 467 bp SacIAgeI fragment from pBBR1MCS-2 causing a frame-shift and premature stop codon at codon position 50. This strain was used to identify suppressor mutants of the impaired colony expansion phenotype. This is strain E⁻ in (1) Δids c. (61) Δids::Tn-Cm(R) carrying plasmid pKG101 pKG101, which encodes promoterless gfp Δids c. (62) Δids::Tn-Cm(R) carrying a pLW101 derivative of pIdsBB in which a FLAG epitope (N-DYKDDDDK-C) was inserted immediately before the idsA stop codon vipA::Tn5 c. (62) vipA::Tn5-Cm(R) carrying pLW101. pLW101 vipA::Tn5-Cm(R) is strain tssA* in (8) BB2000::Δids, CCS05 Δids-derived strain that is Disclosed BB2000::Δids::Tn-Cm(R), vipA_(T95G) vipA_(T95G) deficient in T6SS mediated herein transport CCS05 c. Disclosed Δids::Tn-Cm(R), vipA_(T95G) carrying pLW101 herein pLW101 Δids c. pIdsHI (60) Δids::Tn-Cm(R) carrying plasmid pIdsHI containing the entire HI4320 ids operon (idsA-F) under control of its native promoter CCS05 c. Disclosed Δids::Tn-Cm(R), vipA_(T95G) carrying pIdsBB herein pIdsBB CCS05 c. Disclosed Δids::Tn-Cm(R), vipA_(T95G) carrying pIdsBB-D_(VR-HI)- herein pIdsBB-D_(VR-HI)-E_(VR-BB) E_(VR-BB) CCS05 c. Disclosed Δids::Tn-Cm(R), vipA_(T95G) carrying pIdsBB-D_(VR-BB)- herein pIdsBB-D_(VR-BB)-E_(VR-HI) E_(VR-HI) CCS05 c. Disclosed Δids::Tn-Cm(R), vipA_(T95G) carrying pIdsBB-D_(VR-HI)- herein pIdsBB-D_(VR-HI)-E_(VR-HI) E_(VR-HI) Δids c. CCS06 Δids (export active) Disclosed Δids::Tn-Cm(R) carrying a pIdsBB-ΔE cells producing herein derivative of pIdsBB in which all of D_(VR-BB) and not E idsE has been deleted leaving only the RBS for idsF CCS05 c. CCS05 Disclosed Δids::Tn-Cm(R), vipA_(T95G) carrying pIdsBB-ΔE (export inactive) herein pIdsBB-ΔE cells producing D_(VR-BB) and not E Escherichia coli S17λpir (63) Mating strain for moving plasmids from E. coli into P. mirabilis SM10λpir (57) Mating strain for moving suicide vector pKNG101 into P. mirabilis

Colony Expansion and Coswarm Assays and Viable Cell Counts.

Overnight cultures were normalized to OD₆₀₀ 0.1 and swarm-permissive nutrient plates supplemented with kanamycin were inoculated with 1 microliter of normalized culture. Plates were incubated at 37° C. for 16 hours, and radii of actively migrating swarms were measured. Additionally, widths of individual swarm rings within the swarm colonies were recorded. For coswarm assays, strains were processed as described and mixed at a ratio of 1:1 where indicated. For viable cell counts after 16 hours, actively migrating swarms were resuspended in 6 milliliters of LB medium and 20 microliters of the cell suspension were used for a 10-fold dilution series. A total of 8 dilutions were prepared for each sample and 10 microliters of each dilution were spotted onto LSW⁻ agar supplemented with kanamycin. The dilutions with countable numbers of colonies were used to determine viable cell counts of swarm colonies.

Swimming Assay.

Overnight cultures were normalized to OD₆₀₀ 0.1. An inoculation needle was used to inoculate 0.3% LB nutrient plates supplemented with kanamycin. Plates were incubated at 37° C. for 9 hours and diameters of swim colonies were measured.

Trichloroacetic Acid Precipitations, SDS-PAGE, and Western Blots.

Trichloroacetic acid precipitations were performed as previously described (5). Samples were normalized according to OD₆₀₀ of the liquid cultures at collection, separated by gel electrophoresis using 12% Tris-tricine polyacrylamide gels, transferred onto 0.45-μm nitrocellulose membranes, and probed with monoclonal rabbit-α-FLAG (Sigma-Aldrich, St. Louis, Mo.) and mouse-α-σ⁷⁰ primary antibodies (Thermo Fisher Scientific, Waltham, Mass.), followed by polyclonal goat-α-rabbit (KPL, Inc., Gaithersburg, Md.) and goat-α-mouse secondary antibodies (KPL, Inc., Gaithersburg, Md.), respectively. Membranes were developed with the Immun-Star HRP Substrate Kit (Bio-Rad Laboratories, Hercules, Calif.) and visualized using a Chemidoc (Bio-Rad Laboratories, Hercules, Calif.). TIFF images were exported and figures were made in Adobe Illustrator (Adobe Systems, San Jose, Calif.).

Boundary Assays.

Boundary assays were conducted as previously reported (5). Assays were carried out using swarm-permissive agar plates supplemented with kanamycin.

Plasmid and Strain Construction.

Construction of pIdsBB-ΔE. The pIdsBB-ΔE plasmid was constructed using a 390-basepair (bp) gBlock (Integrated DNA Technologies, Inc., Coralville, Iowa) containing the last 266 bp of idsD, the last 18 bp of idsE and the first 106 bp of idsF. EcoNI and KpnI restriction sites within this fragment were used to replace the sequence between EcoNI and KpnI in pIdsBB (55). Ligations were transformed into One Shot® OmniMax™ 2 T1® chemically competent Escherichia coli (Thermo Fisher Scientific, Waltham, Mass.).

Construction of the vipA mutation. A swarm-capable, spontaneous mutant strain of the BB2000-derived strain lacking full-length E (55) was isolated. This isolate was subjected to phenol-chloroform extractions to isolate genomic DNA (gDNA). gDNA was sheared using a Covaris S 220 (Covaris, Woburn, Mass.), and a library for whole genome sequencing was prepared using the PrepX ILM DNA Library Kit (WaferGen Biosystems, Fremont, Calif.) for the Apollo 324 NGS Library Prep System (WaferGen Biosystems, Fremont, Calif.). The library was sequenced as 100-bp, paired-end reads using an Illumina HiSeq 2500 system (Illumina, San Diego, Calif.). Reads were aligned to the P. mirabilis BB2000 genome (Accession number is CP004022) using Geneious (Biomatters, Auckland, New Zealand). Suppressor-specific polymorphisms were identified by aligning the assembled genome to that of the ancestral strain, BB2000::Δids. The identified mutation mapped to a gene encoding a vipA homolog [T6SS_VipA (PF05591))]. BB2000::/lids, vipA_(T95G) was then constructed by amplifying a DNA fragment using the pCS34 Forward and Reverse primers (Table 3) from gDNA of the isolated spontaneous mutant strain. Restriction digestion with ApaI and XbaI was used to introduce this sequence into the suicide vector pKNG101 (56). The resulting vector pCS34 was introduced into mating strain E. coli SM10λpir (57) and then mated into BB2000::λids. Matings were subjected to antibiotic selection on LSW⁻ agar (15 μm/ml tetracycline and 25 μm/ml streptomycin). Candidate strains were subjected to sucrose counter-selection as previously described (58). Double-recombinants were confirmed using whole genome sequencing as described above. The Bauer Core Facility at Harvard University performed all sequencing.

TABLE 3 DNA sequence inserts and primers for plasmids constructed in this  disclosure. gBlock gene fragment/primer  Plasmid DNA insert/amplified product pair (5′-3′) pIdsBB-ΔE gBlock gene fragment gBlock gene fragment: containing the last 266 bp of GCGAACAATTAAAAATGGCAAG idsD, the last 18 bp of idsE TGAAAAAGGTGATTGGAACCCT and the first 106 bp of idsF. GAAACAGGTATATTTAAATTTA EcoNI and KpnI restriction GTTTGGAAGTACAGTCTCAATTA sites flanking this fragment GTAAATACATATTCTGCTTTTGG were used for cloning into TGCACATCCTAATAGCCGTATA pIdsBB (55). GGTATTGAAGATTTATATTGGTA TTATCAAGTCAATCCCGAGGTA ACAACACCGATGCGTTATATCA ATTGGGGGGGAGATACCCAAGA AAACAATCAGCTTTTAGGCTTTA TTAACAGTGAGAATATCTAAAT CAGGAGAAAGAACACCATGCGT AGTTTGGTAAACGGCAGAAAGA TTATTTTAGAAAATGATACAAC AAATACCGGCGGTACCGTACTT ACCGGCTCTTCTATTGCTAAACA AACACAAGGGG (SEQ ID NO: 17) pCS34 DNA fragment containing Forward primer: vipA as well as the 939 bp CGCGGGCCCGGTATTACCCCAT upstream and the 851 bp AAATAGTGC (SEQ ID NO:18) downstream regions were amplified from genomic DNA of the original suppressor Reverse primer: mutant containing vipA_(T95G) CAGCTATATTTGGTTTAACTTAA GGTCTAGAGCGCGC (SEQ ID NO: 19)

Viable Cell Counts.

Overnight cultures were normalized to OD₆₀₀ 0.1, and swarm-permissive nutrient plates containing 35 μg/ml kanamycin were inoculated with 1 microliter normalized culture. Plates were incubated at 37° C. Viable cell counts at time point 0 were determined by preparing a 10-fold dilution series of the normalized overnight cultures and spotting 10 microliters of each dilution on LSW⁻ agar plates supplemented with kanamycin. Viable cell counts at time points 2, 4, 6 and 8 hours post-inoculation were determined by resuspending swarm colonies in 1 milliliter LB medium and preparing 10-fold dilution series. 10 microliters of each dilution were spotted onto LSW⁻ agar supplemented with kanamycin. Dilutions with countable numbers of colonies were used to determine viable cell counts of swarm colonies.

Measuring Generation Times.

Overnight cultures were normalized to OD₆₀₀ 0.1 in LB medium supplemented with kanamycin. Normalized cultures were grown overnight at 37° C. shaking periodically in a Tecan Infinite® 200 PRO microplate reader (Tecan, Männedorf, Switzerland). Generation times were calculated from log-phase growth measurements.

Phase Contrast Microscopy.

1-mm thick swarm-permissive agar pads supplemented with kanamycin were inoculated from overnight cultures. The agar pads were incubated at 37° C. in a modified humidity chamber. After 5 hours, the pads were imaged by phase contrast microscopy using a Leica DM5500B (Leica Microsystems, Buffalo Grove, Ill.) and a CoolSnap HQ² cooled CCD camera (Photometrics, Tucson, Ariz.). MetaMorph version 7.8.0.0 (Molecular Devices, Sunnyvale, Calif.) was used for image acquisition. Images were acquired every 2 seconds for 78 seconds. Image stacks were imported into Fiji (ImageJ 1.48s) (64-67) where the image stacks were cropped to show a segment of cells, combined into a single movie from four individual movies, and converted to an .AVI file with a frame rate of 5 frames per second.

REFERENCES

-   1. Budding A E, Ingham C J, Bitter W, Vandenbroucke-Grauls C M,     Schneeberger P M. 2009. The Dienes phenomenon: competition and     territoriality in swarming Proteus mirabilis. J Bacteriol     191:3892-3900. -   2. Gibbs K A, Urbanowski M L, Greenberg E P. 2008. Genetic     determinants of self-identity and social recognition in bacteria.     Science 321:256-259. -   3. Senior B W. 1977. The Dienes phenomenon: identification of the     determinants of compatibility. J Gen Microbiol 102:235-244. -   4. Dienes L. 1947. Further observations on the reproduction of     bacilli from large bodies in Proteus cultures. Proc Soc Exp Biol Med     66:97-98. -   5. Wenren L M, Sullivan N L, Cardarelli L, Septer A N, Gibbs     K A. 2013. Two independent pathways for self-recognition in Proteus     mirabilis are linked by type VI-dependent export. mBio 4. -   6. Gibbs K A, Wenren L M, Greenberg E P. 2011. Identity gene     expression in Proteus mirabilis. J Bacteriol 193:3286-3292. -   7. Alteri C J, Himpsl S D, Pickens S R, Lindner J R, Zora J S,     Miller J E, Arno P D, Straight S W, Mobley H L. 2013. Multicellular     bacteria deploy the type VI secretion system to preemptively strike     neighboring cells. PLoS Pathog 9:e1003608. -   8. Mougous J D, Cuff M E, Raunser S, Shen A, Zhou M, Gifford C A,     Goodman A L, Joachimiak G, Ordonez C L, Lory S, Walz T, Joachimiak     A, Mekalanos J J. 2006. A virulence locus of Pseudomonas aeruginosa     encodes a protein secretion apparatus. Science 312:1526-1530. -   9. Pukatzki S, Ma A T, Sturtevant D, Krastins B, Sarracino 317 D,     Nelson W C, Heidelberg J F, Mekalanos J J. 2006. Identification of a     conserved bacterial protein secretion system in Vibrio cholerae     using the Dictyostelium host model system. Proc Natl Acad Sci USA     103:1528-1533. -   10. Pukatzki S, Ma A T, Revel A T, Sturtevant D, Mekalanos     J J. 2007. Type VI secretion system translocates a phage tail     spike-like protein into target cells where it cross-links actin.     Proc Natl Acad Sci USA 104:15508-15513. -   11. Basler M, Pilhofer M, Henderson G P, Jensen G J, Mekalanos     J J. 2012. Type VI secretion requires a dynamic contractile phage     tail-like structure. Nature 483:182-186. -   12. Basler M, Mekalanos J J. 2012. Type 6 secretion dynamics within     and between bacterial cells. Science 337:815. -   13. Basler M, Ho B T, Mekalanos J J. 2013. Tit-for-tat: type VI     secretion system counterattack during bacterial cell-cell     interactions. Cell 152:884-894. -   14. Shneider M M, Buth S A, Ho B T, Basler M, Mekalanos J J, Leiman     P G. 2013. PAAR330 repeat proteins sharpen and diversify the type VI     secretion system spike. Nature 500:350-353. -   15. Hood R D, Singh P, Hsu F, Guvener T, Carl M A, Trinidad R R,     Silverman J M, Ohlson B B, Hicks K G, Plemel R L, Li M, Schwarz S,     Wang W Y, Merz A J, Goodlett D R, Mougous J D. 2010. A type VI     secretion system of Pseudomonas aeruginosa targets a toxin to     bacteria. Cell Host Microbe 7:25-37. -   16. Russell A B, Hood R D, Bui N K, LeRoux M, Vollmer W, Mougous     J D. 2011. Type VI secretion delivers bacteriolytic effectors to     target cells. Nature 475:343-347. -   17. Russell A B, LeRoux M, Hathazi K, Agnello D M, Ishikawa T,     Wiggins P A, Wai S N, Mougous J D. 2013. Diverse type VI secretion     phospholipases are functionally plastic antibacterial effectors.     Nature 496:508-512. -   18. Whitney J C, Chou S, Russell A B, Biboy J, Gardiner 340 T E,     Ferrin M A, Brittnacher M, Vollmer W, Mougous J D. 2013.     Identification, structure, and function of a novel type VI secretion     peptidoglycan glycoside hydrolase effector-immunity pair. J Biol     Chem 288:26616-26624. -   19. Maclntyre D L, Miyata S T, Kitaoka M, Pukatzki S. 2010. The     Vibrio cholerae type VI secretion system displays antimicrobial     properties. Proc Natl Acad Sci USA 107:19520-19524. -   20. Miyata S T, Kitaoka M, Brooks T M, McAuley S B,     Pukatzki S. 2011. Vibrio cholera requires the type VI secretion     system virulence factor VasX to kill Dictyostelium discoideum. Inf     Imm 79:2941-2949. -   21. Brooks T M, Unterweger D, Bachmann V, Kostiuk B,     Pukatzki S. 2013. Lytic activity of the Vibrio cholerae type VI     secretion toxin VgrG-3 is inhibited by the antitoxin TsaB. J Biol     Chem 288:7618-7625. -   22. Unterweger D, Miyata S T, Bachmann V, Brooks T M, Mullins T,     Kostiuk B, Provenzano D, Pukatzki S 2014. The Vibrio cholerae type     VI secretion system employs diverse effector modules for     intraspecific competition. Nature Comm 5:3549. -   23. Durand E, Derrez E, Audoly G, Spinelli S, Ortiz-Lombardia M,     Raoult D, Cascales E, Cambillau C. 2012. Crystal structure of the     VgrG1 actin cross-linking domain of the Vibrio cholerae type VI     secretion system. J Biol Chem 287:38190-38199. -   24. Brunet Y R, Espinosa L, Harchouni S, Mignot T, Cascales E. 2013.     Imaging type VI secretion-mediated bacterial killing. Cell Reports     3:36-41. -   25. Durand E, Nguyen V S, Zoued A, Logger L, Pehau-Arnaudet G,     Aschtgen M S, Spinelli S, Desmyter A, Bardiaux B, Dujeancourt A,     Roussel A, Cambillau C, Cascales E, Fronzes R. 2015. Biogenesis and     structure of a type VI secretion membrane core complex. Nature     523:555-560. -   26. Hachani A, Lossi N S, Hamilton A, Jones C, Bleves S, Albesa-Jove     D, Filloux A. 2011. Type VI secretion system in Pseudomonas     aeruginosa: secretion and multimerization of VgrG proteins. J Biol     Chem 286:12317-12327. -   27. Hachani A, Allsopp L P, Oduko Y, Filloux A. 2014. The VgrG     proteins are “a la carte” delivery systems for bacterial type VI     effectors. J Biol Chem 289:17872-17884. -   28. Ma L S, Hachani A, Lin J S, Filloux A, Lai E M. 2014.     Agrobacterium tumefaciens deploys a superfamily of type VI secretion     DNase effectors as weapons for interbacterial competition in planta.     Cell Host Microbe 16:94-104. -   29. Li M, Le Trong I, Carl M A, Larson E T, Chou S, De Leon J A,     Dove S L, Stenkamp R E, Mougous J D. 2012. Structural basis for type     VI secretion effector recognition by a cognate immunity protein.     PLoS Pathog 8:e1002613. -   30. Miyata S T, Unterweger D, Rudko S P, Pukatzki S 2013. Dual     expression profile of type VI secretion system immunity genes     protects pandemic Vibrio cholerae. PLoS Pathog 9:e1003752. -   31. Cardarelli L, Saak C, Gibbs K A. 2015. Two proteins form a     heteromeric bacterial self recognition complex in which variable     subdomains determine allele-restricted binding. mBio 6:e00251. -   32. Salomon D, Kinch L N, Trudgian D C, Guo X, Klimko J A, Grishin N     V, Mirzaei H, Orth K. 2014. Marker for type VI secretion system     effectors. Proc Natl Acad Sci USA 111:9271-9276. -   33. Bonemann G, Pietrosiuk A, Diemand A, Zentgraf H, Mogk A. 2009.     Remodelling of VipA/VipB tubules by ClpV-mediated threading is     crucial for type VI protein secretion. The EMBO journal 28:315-325. -   34. Kapitein N, Bonemann G, Pietrosiuk A, Seyffer F, Hausser I,     Locker J K, Mogk A. 2013. ClpV recycles VipA/VipB tubules and     prevents non-productive tubule formation to ensure efficient type VI     protein secretion. Mol Microbiol 87:1013-1028. -   35. Silverman J M, Agnello D M, Zheng H, Andrews B T, Li M, Catalano     C E, Gonen T, Mougous J D. 2013. Haemolysin coregulated protein is     an exported receptor and chaperone of type VI secretion substrates.     Mol Cell 51:584-593. -   36. Ruiz F M, Santillana E, Spinola-Amilibia M, Torreira E, Culebras     E, Romero A. 2015. Correction: Crystal Structure of Hcp from     Acinetobacter baumannii: A Component of the Type VI Secretion     System. PloS One 10:e0136978. -   37. Osipiuk J, Xu X, Cui H, Savchenko A, Edwards A,     Joachimiak A. 2011. Crystal structure of secretory protein Hcp3 from     Pseudomonas aeruginosa. Journal Struct Funct Genomics 12:21-26. -   38. Douzi B, Spinelli S, Blangy S, Roussel A, Durand E, Brunet Y R,     Cascales E, Cambillau C. 2014. Crystal structure and     self-interaction of the type VI secretion tail-tube protein from     enteroaggregative Escherichia coli. PloS One 9:e86918. -   39. Gray K M, Passador L, Iglewski B H, Greenberg E P. 1994.     Interchangeability and specificity of components from the     quorum-sensing regulatory systems of Vibrio fischeri and Pseudomonas     aeruginosa. J Bacteriol 176:3076-3080. -   40. Waters C M, Bassler B L. 2005. Quorum sensing: cell-to-cell     communication in bacteria. Annu Rev Cell Dev Biol 21:319-346. -   41. Vannini A, Volpari C, Gargioli C, Muraglia E, Cortese R, De     Francesco R, Neddermann P, Marco S D. 2002. The crystal structure of     the quorum sensing protein TraR bound to its autoinducer and target     DNA. The EMBO journal 21:4393-4401. -   42. Zhang R G, Pappas K M, Brace J L, Miller P C, Oulmassov 409 T,     Molyneaux J M, Anderson J C, Bashkin J K, Winans S C,     Joachimiak A. 2002. Structure of a bacterial quorum-sensing     transcription factor complexed with pheromone and DNA. Nature     417:971-974. -   43. Kaplan H B, Greenberg E P. 1985. Diffusion of autoinducer is     involved in regulation of the Vibrio-Fischeri luminescence system. J     Bacteriol 163:1210-1214. -   44. Pearson J P, Van Delden C, Iglewski B H. 1998. Active efflux and     diffusion are involved in transport of Pseudomonas aeruginosa     cell-to-cell signals. J Bacteriol 181:1203-1210. -   45. Aoki S K, Pamma R, Hernday A D, Bickham J E, Braaten B A, Low     D A. 2005. Contact dependent inhibition of growth in Escherichia     coli. Science 309:1245-1248. -   46. Aoki S K, Malinverni J C, Jacoby K, Thomas B, Pamma R, Trinh B     N, Remers S, Webb J, Braaten B A, Silhavy T J, Low D A. 2008.     Contact-dependent growth inhibition requires the essential outer     membrane protein BamA (YaeT) as the receptor and the inner membrane     transport protein AcrB. Mol Microbiol 70:323-340. -   47. Aoki S K, Diner E J, de Roodenbeke C T, Burgess B R, Poole S J,     Braaten B A, Jones A M, Webb J S, Hayes C S, Cotter P A, Low     D A. 2010. A widespread family of polymorphic contact dependent     toxin delivery systems in bacteria. Nature 468:439-442. -   48. Poole S J, Diner E J, Aoki S K, Braaten B A, t'Kint de     Roodenbeke C, Low D A, Hayes C S. 2011. Identification of functional     toxin/immunity genes linked to contact-dependent growth     inhibition (CDI) and rearrangement hotspot (Rhs) systems. PLoS Genet     7:e1002217. -   49. Diner E J, Beck C M, Webb J S, Low D A, Hayes C S. 2012.     Identification of a target cell permissive factor required for     contact-dependent growth inhibition (CDI). Genes Dev 26:515-525. -   50. Ruhe Z C, Wallace A B, Low D A, Hayes C S. 2013. Receptor     polymorphism restricts contact-dependent growth inhibition to     members of the same species. mBio 4. -   51. Anderson M S, Garcia E C, Cotter P A. 2012. The Burkholderia     bcpAIOB genes define unique classes of two-partner secretion and     contact dependent growth inhibition systems. PLOS Genetics     8:e1002877. -   52. Anderson M S, Garcia E C, Cotter P A. 2014. Kind discrimination     and competitive exclusion mediated by contact-dependent growth     inhibition systems shape biofilm community structure. PLOS Pathog     10:e1004076. -   53. Jones B V, Young R, Mahenthiralingam E, Stickler D J. 2004.     Ultrastructure of Proteus mirabilis swarmer cell rafts and role of     swarming in catheter-associated urinary tract infection. Infect     Immun 72:3941-3950. -   54. Belas R, Erskine D, Flaherty D. 1991. Transposon mutagenesis in     Proteus mirabilis. J Bacteriol 173:6289-6293. -   55. Gibbs K A, Urbanowski M L, Greenberg E P. 2008. Genetic     determinants of self identity and social recognition in bacteria.     Science 321:256-259. -   56. Kaniga K, Delor I, Cornelis G R. 1991. A wide-host-range suicide     vector for improving reverse genetics in gram-negative bacteria:     inactivation of the blaA gene of Yersinia enterocolitica. Gene     109:137-141. -   57. de Lorenzo V, Herrero M, Jakubzik U, Timmis K N. 1990. Mini-Tn5     transposon derivatives for insertion mutagenesis, promoter probing,     and chromosomal insertion of cloned DNA in gram-negative eubacteria.     J Bacteriol 172:6568-6572. -   58. Sturgill G M, Siddiqui S, Ding X, Pecora N D, Rather P N. 2002.     Isolation of lacZ fusions to Proteus mirabilis genes regulated by     intercellular signaling: potential role for the sugar     phosphotransferase (Pts) system in regulation. FEMS Microbiol Lett     217:43-50. -   59. Belas R, Erskine D, Flaherty D. 1991. Transposon mutagenesis in     Proteus mirabilis. J Bacteriol 173:6289-6293. -   60. Cardarelli L, Saak C, Gibbs K A. 2015. Two proteins form a     heteromeric bacterial self recognition complex in which variable     subdomains determine allele-restricted binding. mBio 6:e00251. -   61. Gibbs K A, Wenren L M, Greenberg E P. 2011. Identity gene     expression in Proteus mirabilis. J Bacteriol 193:3286-3292. -   62. Wenren L M, Sullivan N L, Cardarelli L, Septer A N, Gibbs     K A. 2013. Two independent pathways for self-recognition in Proteus     mirabilis are linked by type VI-dependent export. mBio 4. -   63. Simon R, Priefer U, Paler A. 1983. A broad host range     mobilization system for in vivo genetic engineering: transposon     mutagenesis in gram negative bacteria. Nat Biotechnology 1:784-791. -   64. Schneider C A, Rasband W S, Eliceiri K W. 2012. NIH Image to     ImageJ: 25 years of image analysis. Nature methods 9:671-675. -   65. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M,     Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J     Y, White D J, Hartenstein V, Eliceiri K, Tomancak P,     Cardona A. 2012. Fiji: an open-source platform for biological-image     analysis. Nature methods 9:676-682. -   66. Schindelin J, Rueden C T, Hiner M C, Eliceiri K W. 2015. The     ImageJ ecosystem: An open platform for biomedical image analysis.     Molecular reproduction and development 82:518-529. -   67. Pietzsch T, Preibisch S, Tomancak P, Saalfeld S. 2012.     ImgLib2—generic image processing in Java. Bioinformatics     28:3009-3011.

All publications, patents and sequence database entries mentioned herein, including those items listed above, are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

EQUIVALENTS AND SCOPE

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the present invention is not intended to be limited to the above description, but rather is as set forth in the appended claims.

In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention also includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.

Furthermore, it is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the claims or from relevant portions of the description is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Furthermore, where the claims recite a composition, it is to be understood that methods of using the composition for any of the purposes disclosed herein are included, and methods of making the composition according to any of the methods of making disclosed herein or other methods known in the art are included, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.

Where elements are presented as lists, e.g., in Markush group format, it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It is also noted that the term “comprising” is intended to be open and permits the inclusion of additional elements or steps. It should be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements, features, steps, etc., certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements, features, steps, etc. For purposes of simplicity those embodiments have not been specifically set forth in haec verba herein. Thus for each embodiment of the invention that comprises one or more elements, features, steps, etc., the invention also provides embodiments that consist or consist essentially of those elements, features, steps, etc.

Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. It is also to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values expressed as ranges can assume any subrange within the given range, wherein the endpoints of the subrange are expressed to the same degree of accuracy as the tenth of the unit of the lower limit of the range.

In addition, it is to be understood that any particular embodiment of the present invention may be explicitly excluded from any one or more of the claims. Where ranges are given, any value within the range may explicitly be excluded from any one or more of the claims. Any embodiment, element, feature, application, or aspect of the compositions and/or methods of the invention, can be excluded from any one or more claims. For purposes of brevity, all of the embodiments in which one or more elements, features, purposes, or aspects is excluded are not set forth explicitly herein. 

1. A IdsD protein comprising an amino acid sequence as provided by SEQ ID NO:2 or SEQ ID NO:4, or a fragment thereof, wherein the IdsD protein comprises a variable region that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of IdsD protein as provided by SEQ ID NO:10 or SEQ ID NO:12, and wherein the amino acid sequence of the IdsD protein is not identical to the amino acid sequence of a naturally occurring Proteus mirabilis IdsD protein.
 2. The IdsD protein of claim 1, wherein the fragment thereof comprises the variable region comprising an amino acid sequence as provided by SEQ ID NO:10 or SEQ ID NO:12.
 3. The IdsD protein of claim 1, wherein the variable region comprises one or more mutations.
 4. The IdsD protein of claim 3, wherein the one or more mutations are mutations to amino acid residues 761 and/or 765 of amino acid sequences provided by SEQ ID NO:2 or SEQ ID NO:4 or the one or more mutations are mutations to amino acid residues 1 and/or 5 of amino acid sequences provided by SEQ ID NO:10 or SEQ ID NO:12.
 5. The IdsD protein of claim 1, wherein the IdsD protein is provided by nucleic acids encoding the IdsD protein, wherein the nucleic acids are provided by SEQ ID NO:1 or SEQ ID NO:3.
 6. The IdsD protein of claim 2, wherein the IdsD protein is provided by nucleic acids encoding the IdsD protein, wherein the nucleic acids are provided by by SEQ ID NO:9 or SEQ ID NO:11.
 7. The IdsD protein of claim 1, wherein the IdsD protein is provided by a bacterial composition comprising the IdsD protein.
 8. The IdsD protein of claim 7, wherein the bacterial composition comprises Proteus mirabilis.
 9. The IdsD protein of claim 1, wherein the IdsD protein is provided by a pharmaceutical composition comprising the IdsD protein and a pharmaceutically acceptable carrier.
 10. The IdsD protein of claim 1 further comprising one or more therapeutic agents.
 11. (canceled)
 12. A method of reducing bacterial growth and/or swarming on a surface, the method comprising contacting or coating the surface with IdsD protein.
 13. (canceled)
 14. The method of claim 12, wherein the IdsD protein comprises the IdsD protein of claim
 1. 15. A method for reducing the occurrence of urinary tract infections in a subject with a medical device comprising coating of a medical device with IdsD protein and implanting the device in a subject.
 16. (canceled)
 17. The method of claim 15, wherein the IdsD protein comprises the IdsD protein of claim
 1. 18. The method of claim 15, wherein the subject is a human.
 19. A method for treating or preventing a bacterial infection, the method comprising administering to a subject in need thereof a therapeutically effective amount of IdsD protein.
 20. The method of claim 19, wherein the IdsD protein comprises the IdsD protein of claim
 1. 21. The method of claim 19, wherein the bacterial infection is a urinary tract infection.
 22. (canceled)
 23. The method of claim 19, wherein the bacterial infection is a Proteus mirabilis infection. 24-28. (canceled)
 29. A medical device kit comprising a medical device and IdsD protein. 30-31. (canceled) 